1
|
Baltazar D, Zeitouni N, Patel N, Moser J. Neoadjuvant PD-1 Inhibitors: A Tale of Two Cases. J Drugs Dermatol 2024; 23:e57-e59. [PMID: 38306125 DOI: 10.36849/jdd.7043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2024]
Abstract
Treatment responses for locally advanced cutaneous squamous cell carcinoma (cSCC) and Merkel cell carcinoma (MCC) are often short lived and are marred with recurrences. The introduction of adjuvant PD-1 inhibitors has demonstrated significant improvement in both, response rates, and duration of response. For patients with high-risk resectable disease, adjuvant treatments have not demonstrated an ability to reduce recurrence risk. However, there is an opportunity in the neoadjuvant setting to alter recurrence risk. Here we dem-onstrate two cases of neoadjuvant treatment of cSCC and MCC with impressive results. J Drugs Dermatol. 2024;23(2): doi:10.36849/JDD.7043e.
Collapse
|
2
|
Rodriguez A, Moser J, Ramasubramanian A. DNA mismatch repair deficiency in conjunctival melanoma. Eye (Lond) 2023:10.1038/s41433-023-02733-3. [PMID: 37803143 DOI: 10.1038/s41433-023-02733-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2023] [Revised: 08/13/2023] [Accepted: 09/07/2023] [Indexed: 10/08/2023] Open
Affiliation(s)
| | - Justin Moser
- HonorHealth Research and Innovation Institute, Phoenix, AZ, USA
| | | |
Collapse
|
3
|
Zheng J, Brookes A, Moser J, Pfeffer H, Smith A. On the Risk of Nitrosamine Contamination During Drug Product Blister Packaging. J Pharm Sci 2023; 112:2321-2325. [PMID: 37478970 DOI: 10.1016/j.xphs.2023.07.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 07/13/2023] [Accepted: 07/14/2023] [Indexed: 07/23/2023]
Abstract
Most N-Nitrosamine compounds are found to be genotoxic in several animal species. Some are classified as probable or possible human carcinogens and very low acceptable daily intake has been established such as 96 ng/day for N-nitrosodimethylamine (NDMA) and 26.5 ng/N-nitrosodiethylamine (NDEA). The pharmaceutical industry has considered all processing areas for potential formation or contamination of N-nitrosamine. One risk is the potential contamination of nitrosamine during drug product blister packaging using lidding foils containing nitrocellulose, and different approaches have been used by pharmaceutical companies to evaluate and mitigate this risk. Herein we share a perspective from IQ Consortium N-nitrosamine Working Group on some of the approaches and corresponding results. From these assessments, it was concluded that the risk of nitrosamine contamination during blister packaging is negligible. The approaches shared in this perspective can be incorporated into risk assessment for nitrosamine contamination during drug product packaging at other pharmaceutical companies.
Collapse
Affiliation(s)
- Jinjian Zheng
- Analytical Chemistry in Development and Supply, MMD, Merck & Co., Inc, Rahway, NJ, United States.
| | - Andrew Brookes
- Technical Operations, Science and Innovation, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Justin Moser
- Pharmaceutical Sciences & Clinical Supplies, Merck & Co., Inc, West Point, PA, United States
| | - Harvey Pfeffer
- Global Packaging Technology, Merck & Co., Inc, West Point, PA, United States
| | - Andrew Smith
- Device and Packaging Technologies, Global Supply Chain, GSK, Priory Street, Ware, Herts SG12 0DJ, United Kingdom
| |
Collapse
|
4
|
Sundararajan P, Moser J, Williams L, Chiang T, Riordan C, Metzger M, Zhang-Plasket F, Wang F, Collins J, Williams J. Driving Spray Drying towards Better Yield: Tackling a Problem That Sticks Around. Pharmaceutics 2023; 15:2137. [PMID: 37631351 PMCID: PMC10459734 DOI: 10.3390/pharmaceutics15082137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 08/05/2023] [Accepted: 08/09/2023] [Indexed: 08/27/2023] Open
Abstract
Powder deposition and accumulation on walls of spray drying chamber has been known to impact spray drying processes, resulting in lower yield, frequent shutdowns, and downtimes. Critical factors that impact the extent and rate of wall deposition have been studied extensively in the chemical and food industry. In this paper, we present an atypical process yield issue wherein acceptable yield is obtained during the first batch of spray drying but undergoes significant yield loss in consecutive batches. Through understanding the interplay of the process, material properties, and equipment, we identify key mechanisms that are playing a role in causing the process yield issue. These mechanisms include surface roughness of the inner wall of the spray dryer, variation in gas flow due to the introduction of process analytical technology, start-up and shutdown operating parameters that expose the wall deposited powder from the prior batch to temperatures close to the onset of glass transition temperature and cause depression of its glass transition temperature. These factors result in more wall accumulation and impact the yield in subsequent batches. By correcting for most of these factors, the yield reduction issue was mitigated, and processing efficiency was improved.
Collapse
Affiliation(s)
| | - Justin Moser
- Merck & Co., Inc., West Point, PA 19486, USA; (J.M.); (T.C.); (C.R.); (F.Z.-P.)
| | - Lisa Williams
- MSD, Ballydine, E91 V091 Clonmel, Ireland; (L.W.); (J.C.); (J.W.)
| | - Tiffany Chiang
- Merck & Co., Inc., West Point, PA 19486, USA; (J.M.); (T.C.); (C.R.); (F.Z.-P.)
| | - Colin Riordan
- Merck & Co., Inc., West Point, PA 19486, USA; (J.M.); (T.C.); (C.R.); (F.Z.-P.)
| | | | - Fan Zhang-Plasket
- Merck & Co., Inc., West Point, PA 19486, USA; (J.M.); (T.C.); (C.R.); (F.Z.-P.)
| | - Fang Wang
- Merck & Co., Inc., Rahway, NJ 07065, USA; (M.M.); (F.W.)
| | - John Collins
- MSD, Ballydine, E91 V091 Clonmel, Ireland; (L.W.); (J.C.); (J.W.)
| | - Joseph Williams
- MSD, Ballydine, E91 V091 Clonmel, Ireland; (L.W.); (J.C.); (J.W.)
| |
Collapse
|
5
|
Arora M, Moser J, Hoffman TE, Watts LP, Min M, Musteanu M, Rong Y, Ill CR, Nangia V, Schneider J, Sanclemente M, Lapek J, Nguyen L, Niessen S, Dann S, VanArsdale T, Barbacid M, Miller N, Spencer SL. Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity. Cell 2023; 186:2628-2643.e21. [PMID: 37267950 DOI: 10.1016/j.cell.2023.05.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2020] [Revised: 10/10/2022] [Accepted: 05/10/2023] [Indexed: 06/04/2023]
Abstract
CDK2 is a core cell-cycle kinase that phosphorylates many substrates to drive progression through the cell cycle. CDK2 is hyperactivated in multiple cancers and is therefore an attractive therapeutic target. Here, we use several CDK2 inhibitors in clinical development to interrogate CDK2 substrate phosphorylation, cell-cycle progression, and drug adaptation in preclinical models. Whereas CDK1 is known to compensate for loss of CDK2 in Cdk2-/- mice, this is not true of acute inhibition of CDK2. Upon CDK2 inhibition, cells exhibit a rapid loss of substrate phosphorylation that rebounds within several hours. CDK4/6 activity backstops inhibition of CDK2 and sustains the proliferative program by maintaining Rb1 hyperphosphorylation, active E2F transcription, and cyclin A2 expression, enabling re-activation of CDK2 in the presence of drug. Our results augment our understanding of CDK plasticity and indicate that co-inhibition of CDK2 and CDK4/6 may be required to suppress adaptation to CDK2 inhibitors currently under clinical assessment.
Collapse
Affiliation(s)
- Mansi Arora
- Department of Biochemistry and BioFrontiers Institute, University of Colorado-Boulder, Boulder, CO 80303, USA
| | - Justin Moser
- Department of Biochemistry and BioFrontiers Institute, University of Colorado-Boulder, Boulder, CO 80303, USA
| | - Timothy E Hoffman
- Department of Biochemistry and BioFrontiers Institute, University of Colorado-Boulder, Boulder, CO 80303, USA
| | - Lotte P Watts
- Department of Biochemistry and BioFrontiers Institute, University of Colorado-Boulder, Boulder, CO 80303, USA
| | - Mingwei Min
- Department of Biochemistry and BioFrontiers Institute, University of Colorado-Boulder, Boulder, CO 80303, USA; Guangzhou Laboratory, Guangzhou, Guangdong, China
| | - Monica Musteanu
- Experimental Oncology Group, Molecular Oncology Programme, Spanish National Cancer Research Centre, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Yao Rong
- Department of Biochemistry and BioFrontiers Institute, University of Colorado-Boulder, Boulder, CO 80303, USA; Department of Molecular, Cellular, and Developmental Biology and BioFrontiers Institute, University of Colorado-Boulder, Boulder, CO 80303, USA
| | - C Ryland Ill
- Department of Biochemistry and BioFrontiers Institute, University of Colorado-Boulder, Boulder, CO 80303, USA
| | - Varuna Nangia
- Department of Biochemistry and BioFrontiers Institute, University of Colorado-Boulder, Boulder, CO 80303, USA
| | - Jordan Schneider
- Department of Biochemistry and BioFrontiers Institute, University of Colorado-Boulder, Boulder, CO 80303, USA
| | - Manuel Sanclemente
- Experimental Oncology Group, Molecular Oncology Programme, Spanish National Cancer Research Centre, Madrid, Spain
| | - John Lapek
- Oncology Research & Development, Pfizer Worldwide Research & Development, San Diego, CA 92121, USA
| | - Lisa Nguyen
- Oncology Research & Development, Pfizer Worldwide Research & Development, San Diego, CA 92121, USA
| | - Sherry Niessen
- Oncology Research & Development, Pfizer Worldwide Research & Development, San Diego, CA 92121, USA
| | - Stephen Dann
- Oncology Research & Development, Pfizer Worldwide Research & Development, San Diego, CA 92121, USA
| | - Todd VanArsdale
- Oncology Research & Development, Pfizer Worldwide Research & Development, San Diego, CA 92121, USA
| | - Mariano Barbacid
- Experimental Oncology Group, Molecular Oncology Programme, Spanish National Cancer Research Centre, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Nichol Miller
- Oncology Research & Development, Pfizer Worldwide Research & Development, San Diego, CA 92121, USA
| | - Sabrina L Spencer
- Department of Biochemistry and BioFrontiers Institute, University of Colorado-Boulder, Boulder, CO 80303, USA.
| |
Collapse
|
6
|
Szabo Z, Moser J, Vincenti S. Persistent mullerian duct syndrome in a dog. SCHWEIZ ARCH TIERH 2023; 165:189-0. [PMID: 36852872 DOI: 10.17236/sat00389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
INTRODUCTION This case report describes a 14-year-old, male castrated York Shire Terrier, which was presented due to stranguria and tenesmus. An abdominal computed tomography (CT) scan raised a high suspicion of a persistent mullerian duct. During laparotomy structures were found that were suspected to be a persistent ovary and uterus. The abnormal uterus was filled with fluid and had a blind end on both sides. The abnormal structures were surgically removed and pathologically examined. Pathology confirmed a persistent mullerian duct. The patient recovered well from the surgery and was able to urinate spontaneously the same day and was discharged the next day.
Collapse
Affiliation(s)
- Z Szabo
- Abteilung Chirurgie, Departement für Kleintiere, Vetsuisse Fakultät, Universität Bern
| | - J Moser
- Freelance Veterinarian, Schweiz
| | - S Vincenti
- Abteilung Chirurgie, Departement für Kleintiere, Vetsuisse Fakultät, Universität Bern
| |
Collapse
|
7
|
Ashworth IW, Dey D, Dirat O, McDaid P, Lee D, Moser J, Nanda KK. Formation of Dialkyl- N-nitrosamines in Aqueous Solution: An Experimental Validation of a Conservative Predictive Model and a Comparison of the Rates of Dialkyl and Trialkylamine Nitrosation. Org Process Res Dev 2023. [DOI: 10.1021/acs.oprd.2c00366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Affiliation(s)
- Ian W. Ashworth
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Debasis Dey
- Pfizer Healthcare India Private Limited, Chennai 602117, India
| | - Olivier Dirat
- Global CMC, Pfizer Global Product Development, Sandwich CT13 9NJ, United Kingdom
| | - Paul McDaid
- Pfizer Process Development Centre, Global Technology & Engineering, Ringaskiddy, Cork P43 X336, Ireland
| | - Daniel Lee
- Analytical Chemistry in Development and Supply, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Justin Moser
- Global Pharmaceutical Operations Science & Technology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Kausik K. Nanda
- Discovery Pharmaceutical Sciences, Merck & Co., Inc., West Point, Pennsylvania 19846, United States
| |
Collapse
|
8
|
Moser J, Ashworth IW, Harris L, Hillier MC, Nanda KK, Scrivens G. N-Nitrosamine Formation in Pharmaceutical Solid Drug Products: Experimental Observations. J Pharm Sci 2023; 112:1255-1267. [PMID: 36736774 DOI: 10.1016/j.xphs.2023.01.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Revised: 01/25/2023] [Accepted: 01/26/2023] [Indexed: 02/04/2023]
Abstract
The potential presence of N-nitrosamines in medicinal products has become a matter of concern for health authorities and pharmaceutical companies. However, very little information is available in published literature on N-nitrosamine formation within pharmaceutical drug products. In response, experiments were undertaken to test if secondary and tertiary amines present in solid drug products could undergo nitrosation due to the presence of nitrite in the excipients used in the manufacture of the drug product. This work focused on solid dosage forms exploring several model amines of varying chemical structure, solubility and pKa which were formulated using common excipients with and without added nitrite. Monitoring the formation of the N-nitrosamines after processing and upon stressed stability conditions showed that N-nitrosamine formation can occur in solid drug product formulations. The results show that the rate and extent of N-nitrosamine formation depend upon the solubility of the amine, level of nitrite, expected local acidity in water layers within the drug product and mode of processing. Our findings agree with the rank order of dosage form risk from the published EFPIA workflows for quality risk management of N-nitrosamine risks in medicines (EFPIA, 2022): amorphous > wet granulation > direct compression > dry blends. In all cases the level of N-nitrosamine formation in solid dosage forms plateaued at a level that was significantly lower than the maximum theoretical yield based on the level of nitrite present. Trace secondary amine impurities were shown to be a significantly lower risk relative to cases containing a secondary amine present at drug substance levels. A comparison of secondary and simple tertiary alkylamine reactivity showed the tertiary amine to be significantly less reactive with nitrite.
Collapse
Affiliation(s)
- Justin Moser
- Pharmaceutical Sciences & Clinical Supplies, Merck & Co., Inc., West Point, PA, United States.
| | - Ian W Ashworth
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, United Kingdom
| | - Laurence Harris
- Pfizer R&D UK Limited, Discovery Park, Ramsgate Road, Sandwich, CT13 9NJ, United Kingdom
| | - Michael C Hillier
- Operations Science & Technology, API Products, Abbvie Inc. North Chicago, IL, United States
| | - Kausik K Nanda
- Discovery Pharmaceutical Sciences, Merck & Co., Inc., West Point, PA, United States
| | - Garry Scrivens
- Pfizer R&D UK Limited, Discovery Park, Ramsgate Road, Sandwich, CT13 9NJ, United Kingdom
| |
Collapse
|
9
|
Falchook G, Fu S, Lemech C, Mckean M, Azad A, Gan H, Sommerhalder D, Wang J, Tan T, Chee C, Barve M, Moser J, Mooney J, Acuff N, Wang R, Marina N, Abbadessa G, Streit M, Ramusovic S, Meniawy T. 747P Phase I study of SAR444245 (SAR’245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
10
|
Proietti M, Romiti GF, Vitolo M, Harrison SL, Lane DA, Fauchier L, Marin F, Näbauer M, Potpara TS, Dan GA, Maggioni AP, Cesari M, Boriani G, Lip GYH, Ekmekçiu U, Paparisto V, Tase M, Gjergo H, Dragoti J, Goda A, Ciutea M, Ahadi N, el Husseini Z, Raepers M, Leroy J, Haushan P, Jourdan A, Lepiece C, Desteghe L, Vijgen J, Koopman P, Van Genechten G, Heidbuchel H, Boussy T, De Coninck M, Van Eeckhoutte H, Bouckaert N, Friart A, Boreux J, Arend C, Evrard P, Stefan L, Hoffer E, Herzet J, Massoz M, Celentano C, Sprynger M, Pierard L, Melon P, Van Hauwaert B, Kuppens C, Faes D, Van Lier D, Van Dorpe A, Gerardy A, Deceuninck O, Xhaet O, Dormal F, Ballant E, Blommaert D, Yakova D, Hristov M, Yncheva T, Stancheva N, Tisheva S, Tokmakova M, Nikolov F, Gencheva D, Shalganov T, Kunev B, Stoyanov M, Marchov D, Gelev V, Traykov V, Kisheva A, Tsvyatkov H, Shtereva R, Bakalska-Georgieva S, Slavcheva S, Yotov Y, Kubíčková M, Marni Joensen A, Gammelmark A, Hvilsted Rasmussen L, Dinesen P, Riahi S, Krogh Venø S, Sorensen B, Korsgaard A, Andersen K, Fragtrup Hellum C, Svenningsen A, Nyvad O, Wiggers P, May O, Aarup A, Graversen B, Jensen L, Andersen M, Svejgaard M, Vester S, Hansen S, Lynggaard V, Ciudad M, Vettus R, Muda P, Maestre A, Castaño S, Cheggour S, Poulard J, Mouquet V, Leparrée S, Bouet J, Taieb J, Doucy A, Duquenne H, Furber A, Dupuis J, Rautureau J, Font M, Damiano P, Lacrimini M, Abalea J, Boismal S, Menez T, Mansourati J, Range G, Gorka H, Laure C, Vassalière C, Elbaz N, Lellouche N, Djouadi K, Roubille F, Dietz D, Davy J, Granier M, Winum P, Leperchois-Jacquey C, Kassim H, Marijon E, Le Heuzey J, Fedida J, Maupain C, Himbert C, Gandjbakhch E, Hidden-Lucet F, Duthoit G, Badenco N, Chastre T, Waintraub X, Oudihat M, Lacoste J, Stephan C, Bader H, Delarche N, Giry L, Arnaud D, Lopez C, Boury F, Brunello I, Lefèvre M, Mingam R, Haissaguerre M, Le Bidan M, Pavin D, Le Moal V, Leclercq C, Piot O, Beitar T, Martel I, Schmid A, Sadki N, Romeyer-Bouchard C, Da Costa A, Arnault I, Boyer M, Piat C, Fauchier L, Lozance N, Nastevska S, Doneva A, Fortomaroska Milevska B, Sheshoski B, Petroska K, Taneska N, Bakrecheski N, Lazarovska K, Jovevska S, Ristovski V, Antovski A, Lazarova E, Kotlar I, Taleski J, Poposka L, Kedev S, Zlatanovik N, Jordanova S, Bajraktarova Proseva T, Doncovska S, Maisuradze D, Esakia A, Sagirashvili E, Lartsuliani K, Natelashvili N, Gumberidze N, Gvenetadze R, Etsadashvili K, Gotonelia N, Kuridze N, Papiashvili G, Menabde I, Glöggler S, Napp A, Lebherz C, Romero H, Schmitz K, Berger M, Zink M, Köster S, Sachse J, Vonderhagen E, Soiron G, Mischke K, Reith R, Schneider M, Rieker W, Boscher D, Taschareck A, Beer A, Oster D, Ritter O, Adamczewski J, Walter S, Frommhold A, Luckner E, Richter J, Schellner M, Landgraf S, Bartholome S, Naumann R, Schoeler J, Westermeier D, William F, Wilhelm K, Maerkl M, Oekinghaus R, Denart M, Kriete M, Tebbe U, Scheibner T, Gruber M, Gerlach A, Beckendorf C, Anneken L, Arnold M, Lengerer S, Bal Z, Uecker C, Förtsch H, Fechner S, Mages V, Martens E, Methe H, Schmidt T, Schaeffer B, Hoffmann B, Moser J, Heitmann K, Willems S, Willems S, Klaus C, Lange I, Durak M, Esen E, Mibach F, Mibach H, Utech A, Gabelmann M, Stumm R, Ländle V, Gartner C, Goerg C, Kaul N, Messer S, Burkhardt D, Sander C, Orthen R, Kaes S, Baumer A, Dodos F, Barth A, Schaeffer G, Gaertner J, Winkler J, Fahrig A, Aring J, Wenzel I, Steiner S, Kliesch A, Kratz E, Winter K, Schneider P, Haag A, Mutscher I, Bosch R, Taggeselle J, Meixner S, Schnabel A, Shamalla A, Hötz H, Korinth A, Rheinert C, Mehltretter G, Schön B, Schön N, Starflinger A, Englmann E, Baytok G, Laschinger T, Ritscher G, Gerth A, Dechering D, Eckardt L, Kuhlmann M, Proskynitopoulos N, Brunn J, Foth K, Axthelm C, Hohensee H, Eberhard K, Turbanisch S, Hassler N, Koestler A, Stenzel G, Kschiwan D, Schwefer M, Neiner S, Hettwer S, Haeussler-Schuchardt M, Degenhardt R, Sennhenn S, Steiner S, Brendel M, Stoehr A, Widjaja W, Loehndorf S, Logemann A, Hoskamp J, Grundt J, Block M, Ulrych R, Reithmeier A, Panagopoulos V, Martignani C, Bernucci D, Fantecchi E, Diemberger I, Ziacchi M, Biffi M, Cimaglia P, Frisoni J, Boriani G, Giannini I, Boni S, Fumagalli S, Pupo S, Di Chiara A, Mirone P, Fantecchi E, Boriani G, Pesce F, Zoccali C, Malavasi VL, Mussagaliyeva A, Ahyt B, Salihova Z, Koshum-Bayeva K, Kerimkulova A, Bairamukova A, Mirrakhimov E, Lurina B, Zuzans R, Jegere S, Mintale I, Kupics K, Jubele K, Erglis A, Kalejs O, Vanhear K, Burg M, Cachia M, Abela E, Warwicker S, Tabone T, Xuereb R, Asanovic D, Drakalovic D, Vukmirovic M, Pavlovic N, Music L, Bulatovic N, Boskovic A, Uiterwaal H, Bijsterveld N, De Groot J, Neefs J, van den Berg N, Piersma F, Wilde A, Hagens V, Van Es J, Van Opstal J, Van Rennes B, Verheij H, Breukers W, Tjeerdsma G, Nijmeijer R, Wegink D, Binnema R, Said S, Erküner Ö, Philippens S, van Doorn W, Crijns H, Szili-Torok T, Bhagwandien R, Janse P, Muskens A, van Eck M, Gevers R, van der Ven N, Duygun A, Rahel B, Meeder J, Vold A, Holst Hansen C, Engset I, Atar D, Dyduch-Fejklowicz B, Koba E, Cichocka M, Sokal A, Kubicius A, Pruchniewicz E, Kowalik-Sztylc A, Czapla W, Mróz I, Kozlowski M, Pawlowski T, Tendera M, Winiarska-Filipek A, Fidyk A, Slowikowski A, Haberka M, Lachor-Broda M, Biedron M, Gasior Z, Kołodziej M, Janion M, Gorczyca-Michta I, Wozakowska-Kaplon B, Stasiak M, Jakubowski P, Ciurus T, Drozdz J, Simiera M, Zajac P, Wcislo T, Zycinski P, Kasprzak J, Olejnik A, Harc-Dyl E, Miarka J, Pasieka M, Ziemińska-Łuć M, Bujak W, Śliwiński A, Grech A, Morka J, Petrykowska K, Prasał M, Hordyński G, Feusette P, Lipski P, Wester A, Streb W, Romanek J, Woźniak P, Chlebuś M, Szafarz P, Stanik W, Zakrzewski M, Kaźmierczak J, Przybylska A, Skorek E, Błaszczyk H, Stępień M, Szabowski S, Krysiak W, Szymańska M, Karasiński J, Blicharz J, Skura M, Hałas K, Michalczyk L, Orski Z, Krzyżanowski K, Skrobowski A, Zieliński L, Tomaszewska-Kiecana M, Dłużniewski M, Kiliszek M, Peller M, Budnik M, Balsam P, Opolski G, Tymińska A, Ozierański K, Wancerz A, Borowiec A, Majos E, Dabrowski R, Szwed H, Musialik-Lydka A, Leopold-Jadczyk A, Jedrzejczyk-Patej E, Koziel M, Lenarczyk R, Mazurek M, Kalarus Z, Krzemien-Wolska K, Starosta P, Nowalany-Kozielska E, Orzechowska A, Szpot M, Staszel M, Almeida S, Pereira H, Brandão Alves L, Miranda R, Ribeiro L, Costa F, Morgado F, Carmo P, Galvao Santos P, Bernardo R, Adragão P, Ferreira da Silva G, Peres M, Alves M, Leal M, Cordeiro A, Magalhães P, Fontes P, Leão S, Delgado A, Costa A, Marmelo B, Rodrigues B, Moreira D, Santos J, Santos L, Terchet A, Darabantiu D, Mercea S, Turcin Halka V, Pop Moldovan A, Gabor A, Doka B, Catanescu G, Rus H, Oboroceanu L, Bobescu E, Popescu R, Dan A, Buzea A, Daha I, Dan G, Neuhoff I, Baluta M, Ploesteanu R, Dumitrache N, Vintila M, Daraban A, Japie C, Badila E, Tewelde H, Hostiuc M, Frunza S, Tintea E, Bartos D, Ciobanu A, Popescu I, Toma N, Gherghinescu C, Cretu D, Patrascu N, Stoicescu C, Udroiu C, Bicescu G, Vintila V, Vinereanu D, Cinteza M, Rimbas R, Grecu M, Cozma A, Boros F, Ille M, Tica O, Tor R, Corina A, Jeewooth A, Maria B, Georgiana C, Natalia C, Alin D, Dinu-Andrei D, Livia M, Daniela R, Larisa R, Umaar S, Tamara T, Ioachim Popescu M, Nistor D, Sus I, Coborosanu O, Alina-Ramona N, Dan R, Petrescu L, Ionescu G, Popescu I, Vacarescu C, Goanta E, Mangea M, Ionac A, Mornos C, Cozma D, Pescariu S, Solodovnicova E, Soldatova I, Shutova J, Tjuleneva L, Zubova T, Uskov V, Obukhov D, Rusanova G, Soldatova I, Isakova N, Odinsova S, Arhipova T, Kazakevich E, Serdechnaya E, Zavyalova O, Novikova T, Riabaia I, Zhigalov S, Drozdova E, Luchkina I, Monogarova Y, Hegya D, Rodionova L, Rodionova L, Nevzorova V, Soldatova I, Lusanova O, Arandjelovic A, Toncev D, Milanov M, Sekularac N, Zdravkovic M, Hinic S, Dimkovic S, Acimovic T, Saric J, Polovina M, Potpara T, Vujisic-Tesic B, Nedeljkovic M, Zlatar M, Asanin M, Vasic V, Popovic Z, Djikic D, Sipic M, Peric V, Dejanovic B, Milosevic N, Stevanovic A, Andric A, Pencic B, Pavlovic-Kleut M, Celic V, Pavlovic M, Petrovic M, Vuleta M, Petrovic N, Simovic S, Savovic Z, Milanov S, Davidovic G, Iric-Cupic V, Simonovic D, Stojanovic M, Stojanovic S, Mitic V, Ilic V, Petrovic D, Deljanin Ilic M, Ilic S, Stoickov V, Markovic S, Kovacevic S, García Fernandez A, Perez Cabeza A, Anguita M, Tercedor Sanchez L, Mau E, Loayssa J, Ayarra M, Carpintero M, Roldán Rabadan I, Leal M, Gil Ortega M, Tello Montoliu A, Orenes Piñero E, Manzano Fernández S, Marín F, Romero Aniorte A, Veliz Martínez A, Quintana Giner M, Ballesteros G, Palacio M, Alcalde O, García-Bolao I, Bertomeu Gonzalez V, Otero-Raviña F, García Seara J, Gonzalez Juanatey J, Dayal N, Maziarski P, Gentil-Baron P, Shah D, Koç M, Onrat E, Dural IE, Yilmaz K, Özin B, Tan Kurklu S, Atmaca Y, Canpolat U, Tokgozoglu L, Dolu AK, Demirtas B, Sahin D, Ozcan Celebi O, Diker E, Gagirci G, Turk UO, Ari H, Polat N, Toprak N, Sucu M, Akin Serdar O, Taha Alper A, Kepez A, Yuksel Y, Uzunselvi A, Yuksel S, Sahin M, Kayapinar O, Ozcan T, Kaya H, Yilmaz MB, Kutlu M, Demir M, Gibbs C, Kaminskiene S, Bryce M, Skinner A, Belcher G, Hunt J, Stancombe L, Holbrook B, Peters C, Tettersell S, Shantsila A, Lane D, Senoo K, Proietti M, Russell K, Domingos P, Hussain S, Partridge J, Haynes R, Bahadur S, Brown R, McMahon S, Y H Lip G, McDonald J, Balachandran K, Singh R, Garg S, Desai H, Davies K, Goddard W, Galasko G, Rahman I, Chua Y, Payne O, Preston S, Brennan O, Pedley L, Whiteside C, Dickinson C, Brown J, Jones K, Benham L, Brady R, Buchanan L, Ashton A, Crowther H, Fairlamb H, Thornthwaite S, Relph C, McSkeane A, Poultney U, Kelsall N, Rice P, Wilson T, Wrigley M, Kaba R, Patel T, Young E, Law J, Runnett C, Thomas H, McKie H, Fuller J, Pick S, Sharp A, Hunt A, Thorpe K, Hardman C, Cusack E, Adams L, Hough M, Keenan S, Bowring A, Watts J, Zaman J, Goffin K, Nutt H, Beerachee Y, Featherstone J, Mills C, Pearson J, Stephenson L, Grant S, Wilson A, Hawksworth C, Alam I, Robinson M, Ryan S, Egdell R, Gibson E, Holland M, Leonard D, Mishra B, Ahmad S, Randall H, Hill J, Reid L, George M, McKinley S, Brockway L, Milligan W, Sobolewska J, Muir J, Tuckis L, Winstanley L, Jacob P, Kaye S, Morby L, Jan A, Sewell T, Boos C, Wadams B, Cope C, Jefferey P, Andrews N, Getty A, Suttling A, Turner C, Hudson K, Austin R, Howe S, Iqbal R, Gandhi N, Brophy K, Mirza P, Willard E, Collins S, Ndlovu N, Subkovas E, Karthikeyan V, Waggett L, Wood A, Bolger A, Stockport J, Evans L, Harman E, Starling J, Williams L, Saul V, Sinha M, Bell L, Tudgay S, Kemp S, Brown J, Frost L, Ingram T, Loughlin A, Adams C, Adams M, Hurford F, Owen C, Miller C, Donaldson D, Tivenan H, Button H, Nasser A, Jhagra O, Stidolph B, Brown C, Livingstone C, Duffy M, Madgwick P, Roberts P, Greenwood E, Fletcher L, Beveridge M, Earles S, McKenzie D, Beacock D, Dayer M, Seddon M, Greenwell D, Luxton F, Venn F, Mills H, Rewbury J, James K, Roberts K, Tonks L, Felmeden D, Taggu W, Summerhayes A, Hughes D, Sutton J, Felmeden L, Khan M, Walker E, Norris L, O’Donohoe L, Mozid A, Dymond H, Lloyd-Jones H, Saunders G, Simmons D, Coles D, Cotterill D, Beech S, Kidd S, Wrigley B, Petkar S, Smallwood A, Jones R, Radford E, Milgate S, Metherell S, Cottam V, Buckley C, Broadley A, Wood D, Allison J, Rennie K, Balian L, Howard L, Pippard L, Board S, Pitt-Kerby T. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe. Age Ageing 2022; 51:6670566. [PMID: 35997262 DOI: 10.1093/ageing/afac192] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Revised: 06/08/2022] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND Frailty is a medical syndrome characterised by reduced physiological reserve and increased vulnerability to stressors. Data regarding the relationship between frailty and atrial fibrillation (AF) are still inconsistent. OBJECTIVES We aim to perform a comprehensive evaluation of frailty in a large European cohort of AF patients. METHODS A 40-item frailty index (FI) was built according to the accumulation of deficits model in the AF patients enrolled in the ESC-EHRA EORP-AF General Long-Term Registry. Association of baseline characteristics, clinical management, quality of life, healthcare resources use and risk of outcomes with frailty was examined. RESULTS Among 10,177 patients [mean age (standard deviation) 69.0 (11.4) years, 4,103 (40.3%) females], 6,066 (59.6%) were pre-frail and 2,172 (21.3%) were frail, whereas only 1,939 (19.1%) were considered robust. Baseline thromboembolic and bleeding risks were independently associated with increasing FI. Frail patients with AF were less likely to be treated with oral anticoagulants (OACs) (odds ratio 0.70, 95% confidence interval 0.55-0.89), especially with non-vitamin K antagonist OACs and managed with a rhythm control strategy, compared with robust patients. Increasing frailty was associated with a higher risk for all outcomes examined, with a non-linear exponential relationship. The use of OAC was associated with a lower risk of outcomes, except in patients with very/extremely high frailty. CONCLUSIONS In this large cohort of AF patients, there was a high burden of frailty, influencing clinical management and risk of adverse outcomes. The clinical benefit of OAC is maintained in patients with high frailty, but not in very high/extremely frail ones.
Collapse
Affiliation(s)
- Marco Proietti
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.,Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy
| | - Giulio Francesco Romiti
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Translational and Precision Medicine, Sapienza - University of Rome, Italy
| | - Marco Vitolo
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.,Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy
| | - Stephanie L Harrison
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK
| | - Deirdre A Lane
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | - Laurent Fauchier
- Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, Tours, France
| | - Francisco Marin
- Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, CIBER-CV, Murcia, Spain
| | - Michael Näbauer
- Department of Cardiology, Ludwig-Maximilians-University, Munich, Germany
| | - Tatjana S Potpara
- School of Medicine, University of Belgrade, Belgrade, Serbia.,Clinical Center of Serbia, Belgrade, Serbia
| | - Gheorghe-Andrei Dan
- University of Medicine, 'Carol Davila', Colentina University Hospital, Bucharest, Romania
| | - Aldo P Maggioni
- ANMCO Research Center, Heart Care Foundation, Florence, Italy
| | - Matteo Cesari
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.,Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy
| | - Giuseppe Boriani
- Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
| | - Gregory Y H Lip
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Moser J, Keire D, Schlingemann J, Saal C. N -nitrosamines Impurities in Pharmaceuticals The abrupt challenges they bring and approaches to tackle the risk. J Pharm Sci 2022; 111:2651. [PMID: 35901944 DOI: 10.1016/j.xphs.2022.07.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Accepted: 07/21/2022] [Indexed: 11/16/2022]
Affiliation(s)
- Justin Moser
- Merck & Co., Inc. 770 Sumneytown Pike WP78-110 West Point, Pa 19486, United States of America
| | - David Keire
- US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, 645 S Newstead Ave., St Louis, MO, 63110, United States of America
| | - Jörg Schlingemann
- Merck Healthcare KGaA, Frankfurter Straße 250, 64293 Darmstadt, Germany
| | - Christoph Saal
- Merck KGaA, Frankfurter Straße 250, 64293 Darmstadt, Germany.
| |
Collapse
|
12
|
Dorigo O, Contag PR, Moser J, Patel SP, Frohlich MW. Abstract CT176: A phase 1 open label, first in human trial to study safety and tolerability of NK-T cells combined with vvDD: An accelerated dose escalation in multiple tumor types. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-ct176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: BioEclipse Therapeutics has developed CRX100 an adoptive NK-T Cells therapy combined with vaccinia vvDD, an oncolytic virus. vvDD is a Western Reserve (WR) strain vaccinia virus (VACV) that has been further attenuated by the removal of the viral thymidine kinase and growth factor genes, and hence its replication and lytic activity is confined to tumor cells. In preclinical studies in immunocompetent mice the combined therapy eradicated tumor cells and initiated an adaptive immune response.
Trial Design: Our ongoing phase 1 safety clinical trial (IND 19222 at Clinicaltrials.gov) began in January 2021 and includes planned treatment of approximately 24 patients with the potential for 2 doses each. With the dose of ex vivo activated autologous NK-T cells held constant (2-5 X 109), the dose of vvD is increased at 5 dose levels, 3X107, 1x108, 3x108, 1x109 and 3x109 pfu/dose. The first five doses are accelerated in cohorts of one patient and followed by a non-accelerated phase with a cohort of two patients and then 3 cohorts of three patients to determine the MTD, with an additional 8 patients then treated at the MTD. Dose limiting toxicities evaluated by a BOIN design will assist in the dose decision for phase 2.
Inclusion and exclusion criteria: Patients will have tumor progression and have failed standard of care in the indications, triple negative breast cancer, gastric cancer, colorectal carcinoma, hepatocellular carcinoma, ovarian cancer or osteosarcoma.
Results: To date, 4 patients have been treated, including 2 patients with ovarian cancer and 2 with CRC at 4 dose levels. No dose limiting toxicities have been observed. The most common AE is mild fever at 6-12 hours after infusion. Two CRC patients treated at a vvDD dose of 3x107 and 1x109 experienced disease progression. Patient 101-005 with ovarian cancer received two separate infusions 3 months apart each at a dose of 1x108 PFU vvDD combined with 2-5 X 109 ex-vivo activated autologous NKT. Tumor assessment after the first dose showed stable disease (+17.2%) by iRECIST. The CA125 serum biomarker increased temporarily about 3 weeks after infusion. The second ovarian patient (101-007) treated with 3x108 vvDD combined with 2-5 X 109 ex-vivo activated autologous NKT had unconfirmed progression (+21%). There was a slight increase and then a decrease of the CA-125 from 303 to 268. The patient developed new ascites 4 weeks after infusion and required a paracentesis. The ascites did not recur after the paracentesis.
Conclusion: Thus far in escalation, all doses of the therapy have been safe and well-tolerated. Two patients with ovarian cancer treated with the adoptive NKT cell therapy combined with an oncolytic virus demonstrated changes in CA-125 potentially consistent with immune inflammation. Peripheral blood obtained at 3 and 6 month will be analyzed to assess specific immune responses. Dose escalation and enrollment continue for this study.
Citation Format: Oliver Dorigo, Pamela Reilly Contag, Justin Moser, Sandip Pravin Patel, Mark W. Frohlich. A phase 1 open label, first in human trial to study safety and tolerability of NK-T cells combined with vvDD: An accelerated dose escalation in multiple tumor types [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT176.
Collapse
Affiliation(s)
| | | | - Justin Moser
- 3HonorHealth Research Inst. and U of Az College of Med., Scottsdale, AZ
| | | | | |
Collapse
|
13
|
In GK, Yin J, Walker P, Moser J, Xiu J, Poorman K, Gibney GT, Oberley M, Phung T, Hernandez-Aya LF, Lutzky J, Korn WM, Atkins MB. Abstract 6130: Comprehensive genomic and transcriptomic profiling of acral lentiginous melanoma. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-6130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Acral lentiginous melanoma (ALM) is a rare melanoma subtype found on the palms, soles and nailbeds. Outcomes are poor for patients with advanced ALM, and novel treatment approaches are needed. Here, we seek to explore the global genomic and transcriptomic landscape of ALM.
Methods: A total of 699 primary CM (non-ALM cutaneous melanoma) and 18 primary ALM samples underwent next generation sequencing of DNA (592 Gene Panel, NextSeq, or WES, NovaSeq), and whole transcriptome sequencing (NovaSeq, WTS). Wilcoxon, Fisher’s exact test were used to determine statistical significance (displayed as p value without and q value with multi comparison correction). xCell, HLA subtyping, neoantigen load (HBA: high binding affinity; IBA: intermediate binding affinity; LBA: low binding affinity), Interferon gamma score (IFNγ), MAPK pathway activity score (MPAS), and Innate anti-PD-1 Resistance score (IPRES) were calculated by mRNA expression. Global differentially regulated genes were assessed via limma R package (C: log fold change).
Results: The most common alterations in ALM included NRAS (22.2%), NF1 (20.0%), BRAF (11.1%) and CDKN2A (11.1%) mutations, and EMSY (22.2%), ELL (11.1%), MAML2 (11.1%), MRE11(11.1%) and PIK3R2 (11.1%) amplifications. ALM had lower TMB (1.5 v 9 Mut/Mb, q<.0001), lower rates of TERT (0 v 66.7%, q<.01) and a trend towards lower BRAF (11.1 v 39.8%, p<.05) mutations, compared to CM. Neoantigen load was lower in ALM compared to CM, regardless of MHC binding affinity (HBA: 1 vs 4, q <.01; IBA: 2 vs 7, q <.001; LBA: 7 vs 18, q <.001). HLA-G RNA expression was upregulated in ALM with respect to CM (C = 1.14, q <.001). ALM showed less CD4+ T cell Th1 (C = -0.8, p <.05), B cell plasma (C = -1.8, p<.05), and γδ T cells (C = -5.9, p<.05), but more CD4+ T cell central memory cell (C = 9.7, p<.05), stroma score (C = 1.7, p<.05), and endothelial cells (C = 1.7, p<.05), versus CM. There was a trend towards lower IFNγ in ALM (-0.4 vs -0.3, p = .1), but no difference in IPRES, compared to CM (-0.09 vs 0.1, p=.9). MPAS scores were lower for ALM compared to CM (-1.6 vs -0.4, q<.001), even when stratifying by BRAF (q<.05) or NF1 (q<.05) status, but not NRAS (p = .22). Pathways related to keratinization (p <.0001) and amyloid fiber formation (p<.0001) were enriched in ALM, due to overexpression of KRT16 (C = 3.5, q <.01), KRT6B (C = 3.4, q <.01), and KRT17 (C = 3.2, q <.05), among others.
Conclusion: ALM has distinct immunologic features, including upregulation of HLA-G, as well as lower MAPK activation in ALM, compared to CM, highlighting the need for novel therapeutic approaches in the treatment of this rare subtype.
Citation Format: Gino K. In, Jun Yin, Phillip Walker, Justin Moser, Joanne Xiu, Kelsey Poorman, Geoffery T. Gibney, Matthew Oberley, Thuy Phung, Leonel F. Hernandez-Aya, Jose Lutzky, Wolfgang Michael Korn, Michael B. Atkins. Comprehensive genomic and transcriptomic profiling of acral lentiginous melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6130.
Collapse
Affiliation(s)
- Gino K. In
- 1University of Southern California, Los Angeles, CA
| | - Jun Yin
- 2Caris Life Sciences, Tempe, AZ
| | | | | | | | | | | | | | - Thuy Phung
- 6University of South Alabama, Mobile, AL
| | | | - Jose Lutzky
- 7University of Miami Miller School of Medicine, Miami, FL
| | | | | |
Collapse
|
14
|
Hernandez-Aya LF, Rodriguez E, Nallagangula A, Yin J, Walker P, Xiu J, Moser J, In GK, Spetzler D, Gibney GT, Oberley M, Phung T, Atkins M, Hoon DS, Korn WM, Lutzky J, Lopes G. Abstract 5625: Molecular and immunologic characterization of HRAS mutations in a cohort of 6,329 patients with cutaneous melanoma. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-5625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Activation in RAS pathway has been associated with cancer development. Three RAS family members, including NRAS, KRAS and HRAS are frequently mutated across various cancer types, where NRAS mutations are present in 15-20% of melanomas. NRAS-mutant melanomas (NRASm) have been extensively characterized. However, molecular and clinical implications of HRAS mutations (HRASm) in melanoma are less well understood.
Methods: A total of 6329 melanoma samples were subjected to comprehensive molecular profiling at Caris Life Sciences. Analyses included next generation sequencing of DNA (592 Gene Panel, NextSeq; whole exome sequencing, NovaSEQ), RNA (NovaSeq, whole transcriptome sequencing, WTS) and IHC. MPAS scores to evaluate MAPK pathway activation, IFN scores, QuantiSeq, neoantigen load (high, intermediate, low binding affinity: HBA, IBA and LBA) and GSEA were calculated from mRNA expression data. Wilcoxon, Fisher’s exact were used to determined statistical significance (p value without and q value with multi comparison correction; FDR for GSEA). The reference cohort was the entire melanoma cohort (MC).
Results: HRASm were identified in 69 (1.09%) of melanoma samples (hotspots mutations: G13, 40%; Q61, 34%; G12, 18% and others, 9%). HRASm and NRASm had different genomic landscapes: HRASm were significantly associated with a higher mutation rate of NF1 (43.2% vs 27.7%, p<.05), ARID1A (17.2% vs 6.3%, p<.05), B2M (14.3% vs 2.4%, p<.05), RAF1 (12.2% vs 1.4, p<.0001), CTNNB1 (9.1% vs 3.3%, p<.05) and higher amplifications of EMSY (11.8% vs 1.8%, p<.01), MRE11 (4.3% vs 0.5%, p<.05), whereas NRASm harbored less NF1 (14.8% vs 27.7%, q<.0001 ), BRAF (6.9% vs 39.9%, p <.0001), PTEN (3.9% vs 6.9%, q <.05), KIT (0.8% vs 4.4%, q <.0001) mutations and less amplification PDGFR (0.4% vs 1.3%, p<.05), BRAF (0.2% vs 1.4%, p<.05), KIT (0.2% vs 2.1%, q<.05) when comparing to MC. Both HRASm and NRASm had higher MPAS scores than MC (HRASm, 0.24; NRASm, 0.11; MC, -0.41, q<.001). In addition, HRASm showed higher TMB (HRASm, 68.1%; NRASm, 56.9%; MC, 50.0%, q<.05), relatively higher IFN scores (HRASm, 0.16; NRASm, -0.23; MC, -0.24, q = .16) and higher neoantigen load (HBA: HRASm, 10.5; NRASm, 4; MC, 4, p < .05; IBA: HRASm, 17.5; NRASm, 8 MC, 7, p < .05; LBA: HRASm, 37.5; NRASm, 21; MC, 19, p =.1) when compared to NRASm and MC. Lastly, suppression of angiogenesis pathway was observed in both HRASm (NES = 1.7, FDR<.05) and NRASm with respect to MC (NES = 1.4, FDR<.25).
Conclusions: The genomic landscape of HRASm are significantly different from that of NRASm, implying their distinct roles in tumorigenesis. HRASm also demonstrated higher MAPK activation, suggesting that they could potentially benefit from agents targeting on this pathway. In addition, HRASm displayed more immunogenic features, associated with down-regulation of angiogenesis pathway, revealing a potential higher susceptibility of HRASm to immunotherapy.
Citation Format: Leonel F. Hernandez-Aya, Estelamari Rodriguez, Aparna Nallagangula, Jun Yin, Phillip Walker, Joanne Xiu, Justin Moser, Gino K. In, David Spetzler, Geoffery T. Gibney, Matthew Oberley, Thuy Phung, Michael Atkins, Dave S. Hoon, Wolfgang Michael Korn, Jose Lutzky, Gilberto Lopes. Molecular and immunologic characterization of HRAS mutations in a cohort of 6,329 patients with cutaneous melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5625.
Collapse
Affiliation(s)
| | | | - Aparna Nallagangula
- 2Sylvester Comprehensive Cancer Center at the University of Miami, Miami, FL
| | - Jun Yin
- 3Caris Life Sciences, Tempe, AZ
| | | | | | | | - Gino K. In
- 5USC Keck School of Medicine, USC Norris Comprehensive Cancer Center, Los Angeles, CA
| | | | | | | | - Thuy Phung
- 8University of South Alabama, Mobile, AL
| | - Michael Atkins
- 6Medstar/Georgetown University Medical Center, Washington, DC
| | - Dave S. Hoon
- 9Saint John’s Cancer Institute, Santa Monica, CA
| | | | - Jose Lutzky
- 1University of Miami Miller School of Medicine, Miami, FL
| | - Gilberto Lopes
- 2Sylvester Comprehensive Cancer Center at the University of Miami, Miami, FL
| |
Collapse
|
15
|
Bullock A, Grossman J, Fakih M, Lenz H, Gordon M, Margolin K, Wilky B, Mahadevan D, Trent J, Bockorny B, Moser J, Balmanoukian A, Schlechter B, Ortuzar Feliu W, Rosenthal K, Bullock B, Stebbing J, Godwin J, O'Day S, Tsimberidou A, El-Khoueiry A. LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
16
|
Lemoine M, My I, Mencke C, Butt M, Schleberger R, Muenkler P, Rottner L, Moser F, Moser J, Dinshaw L, Reissmann B, Ouyang F, Kirchhof P, Rillig A, Metzner A. Comparison of left atrial lesion size and troponin release of two novel single shot devices for pulmonary vein isolation: pulsed field ablation vs. multi-electrode radiofrequency balloon. Europace 2022. [DOI: 10.1093/europace/euac053.253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction
Pulsed-field ablation (PFA) and the multi-electrode radiofrequency balloon (RFB) are two novel ablation technologies to perform pulmonary vein isolation (PVI). It is currently unknown whether these technologies differ in lesion formation and lesion extent.
Purpose
We compared the acute lesion extent after PVI induced by PFA and RFB by measuring low-voltage area in high-density maps and the release of biomolecules reflecting cardiac injury.
Methods
PVI was performed with a pentaspline catheter (FARAPULSE) applying PFA or with the compliant multi-electrode radiofrequency balloon (HELIOSTAR). Before and after PVI high-density mapping with CARTO3 was performed. In addition, blood samples were taken before transseptal puncture and after post-PVI remapping. Serum concentrations of high-sensitive Troponin I (hsTropI) were quantified by Immunoassay.
Results
50 patients undergoing PVI by PFA (n=26, age 71±10 y, 58% males, 58% persistent AF) or RFB (n=24; age 64±13 y, 54% males, 25% persistent AF) were evaluated. Acute PVI was achieved in all patients in both groups. Mean number of PFA pulses were n=34±5 and mean number RFB applications were n=8±3. Total posterior ablation area was bigger in PFA (19.0±6.2 cm²) than in RFB (9.0±2.2 cm²; p<0.001). The posterior distance between septal and lateral lesions was shorter in PFA (23.7±10.5 mm) than in RFB (30.0±7.3 mm; p=0.021). In a total of 38 patients increase of hsTropI was higher after PFA (625±138 pg/ml, n=28) vs. RFB (148±36 pg/ml; n=10; p=0.049) supporting the evidence of larger lesion extent by PFA.
Conclusion
Pulse-field ablation delivers larger acute lesion areas and higher troponin release upon successful pulmonary vein isolation than multi-electrode array balloon-based pulmonary vein isolation in this single-center series.
Collapse
Affiliation(s)
- M Lemoine
- University Heart Center Hamburg, Department of Cardiology and Electrophysiology, Hamburg, Germany
| | - I My
- University Heart Center Hamburg, Department of Cardiology and Electrophysiology, Hamburg, Germany
| | - C Mencke
- University Heart Center Hamburg, Department of Cardiology and Electrophysiology, Hamburg, Germany
| | - M Butt
- University Heart Center Hamburg, Department of Cardiology and Electrophysiology, Hamburg, Germany
| | - R Schleberger
- University Heart Center Hamburg, Department of Cardiology and Electrophysiology, Hamburg, Germany
| | - P Muenkler
- University Heart Center Hamburg, Department of Cardiology and Electrophysiology, Hamburg, Germany
| | - L Rottner
- University Heart Center Hamburg, Department of Cardiology and Electrophysiology, Hamburg, Germany
| | - F Moser
- University Heart Center Hamburg, Department of Cardiology and Electrophysiology, Hamburg, Germany
| | - J Moser
- University Heart Center Hamburg, Department of Cardiology and Electrophysiology, Hamburg, Germany
| | - L Dinshaw
- University Heart Center Hamburg, Department of Cardiology and Electrophysiology, Hamburg, Germany
| | - B Reissmann
- University Heart Center Hamburg, Department of Cardiology and Electrophysiology, Hamburg, Germany
| | - F Ouyang
- University Heart Center Hamburg, Department of Cardiology and Electrophysiology, Hamburg, Germany
| | - P Kirchhof
- University Heart Center Hamburg, Department of Cardiology and Electrophysiology, Hamburg, Germany
| | - A Rillig
- University Heart Center Hamburg, Department of Cardiology and Electrophysiology, Hamburg, Germany
| | - A Metzner
- University Heart Center Hamburg, Department of Cardiology and Electrophysiology, Hamburg, Germany
| |
Collapse
|
17
|
Obergassel J, Rottner L, Schleberger R, Moser F, Moser J, Dinshaw L, Lemoine MD, My I, Kirchhof P, Reissmann B, Metzner A, Rillig A. Shortened fluoroscopy duration and reduced use of contrast dye in cryoballoon-based pulmonary vein isolation procedures using KODEX-EPD’s novel occlusion tool. Europace 2022. [DOI: 10.1093/europace/euac053.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Private company. Main funding source(s): Study grant by EPD Solutions, Philips, Netherlands
Background
The occlusion tool was recently introduced for KODEX-EPD which is a novel dielectric high-resolution cardiac imaging system. The occlusion tool provides information about level of pulmonary vein occlusion by the cryoballoon (CB) in CB-based pulmonary vein isolation (PVI) ablation procedures for atrial fibrillation (AF).
Purpose
Assess effects of the introduction of the occlusion tool on procedural parameters during CB-PVI such as feasibility, acute efficacy and periprocedural safety of KODEX-EPD in different software versions.
Methods and Results
173 consecutive patients (60/173 (35%) paroxysmal AF, 64±12 years, 66/173 (38%) female) underwent CB-PVI with EPD imaging between 08/2019 and 10/2021. 38/173 (22%) of all patients were treated using software version 1.4.6, 33/173 (19%) patients with version 1.4.6a, 41/173 (24%) patients with version 1.4.7 and 61/173 (35%) patients with the latest version 1.4.8. Acute PVI was achieved in all patients. No major periprocedural complications were documented. Software version showed significant effects on procedure duration, fluoroscopy duration and dose area product in ANOVA testing (Figure 1A-C). The largest effect in post-hoc testing was observed for fluoroscopy duration (Figure 1B). Tobit regressions were fitted to model effects of software version on the censored variable contrast volume. All software versions predicted used contrast volume (p<0.00748, Figure 1D). Modelling only effects of procedure date on contrast volume was less accurate than for software version (r²=0.057, p for procedure date = 0.0031) and also a Likelihood-Ratio-Test between different regression models underlined significant effects of software version (p<0.0001).
Conclusion
CB-based PVI in combination with its PV-occlusion tool is feasible and safe. The present data strongly suggests a steady positive development of the novel wide-band dielectric imaging and mapping system towards a fluoroscopy- and dye-reduced CB-based AF-ablation. Software versions were introduced sequentially. Therefore time (procedure date) needs to be considered as the most relevant confounder of the described results (e.g. due to a learning curve using the system). However, differentiated statistical testing could show that the results are mainly explained by software version and only much weaker by procedure date.
Collapse
Affiliation(s)
- J Obergassel
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - L Rottner
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - R Schleberger
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - F Moser
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - J Moser
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - L Dinshaw
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - MD Lemoine
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - I My
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - P Kirchhof
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - B Reissmann
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - A Metzner
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - A Rillig
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| |
Collapse
|
18
|
Moser J, Unverdorben M, Wang CC, Bruggenjurgen B, Lee BC, Chen C, Pecen L, Yamashita T, De Caterina R, Kirchhof P. Effectiveness and safety of edoxaban in 27,333 patients from ETNA-AF with and without a history of intracranial haemorrhage after 2 years of treatment. Europace 2022. [DOI: 10.1093/europace/euac053.288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Private company. Main funding source(s): This study was sponsored by Daiichi Sankyo, Inc. Medical writing and editorial support were provided by Atreju Lackey, PhD of AlphaBioCom, LLC, and funded by Daiichi Sankyo, Inc.
Background/Introduction
Once-daily edoxaban significantly reduced the risk of intracranial haemorrhage (ICH) compared with well-managed warfarin in atrial fibrillation (AF) patients in the ENGAGE AF-TIMI 48 trial. The effectiveness and safety of edoxaban in patients with prior ICH is unknown.
Purpose
To compare the effectiveness and safety of edoxaban in AF patients with or without a history of ICH.
Methods
The Global ETNA-AF programme is composed of and, thus, integrates data from multiple prospective, observational, and noninterventional regional studies collecting data of AF patients treated with edoxaban for stroke prevention. This snapshot analysis presents global and regional baseline characteristics with medical history and 2-year annualised rates of all-cause mortality, stroke (haemorrhagic, ischaemic, any), and bleeding (major bleeding [MB] including ICH, clinically relevant nonmajor bleeding [CRNMB], any bleeding), in patients with or without ICH history.
Results
Overall, 27,333 patients from Europe, Japan, South Korea, and Taiwan were analysed, including 367 with prior ICH and 26,966 without prior ICH. There were proportionally fewer patients with a history of ICH in the European population. Patients with a history of ICH were older (P=0.006), had a lower body mass index (P<0.0001), had a lower creatinine clearance (P=0.0001), and had more comorbidities, with a higher percentage of patients with a history of stroke, transient ischaemic attack (TIA), or MB (Table 1); the higher level of comorbidities noted in patients with a history of ICH was also reflected by higher baseline CHA2DS2-VASc and HAS-BLED scores (Table 1). Patients with a history of ICH were more likely receiving 30 mg edoxaban at baseline, whereas patients without ICH history were more often on 60 mg edoxaban (each P<0.0001). In patients with vs without ICH history, all-cause mortality (5.10% vs 3.14%; P=0.01), ischaemic stroke (1.79% vs 0.73%; P=0.006), and any stroke rates (3.25% vs 0.95%; P<0.0001) were higher (Table 2). Patients with vs without ICH history had higher annualised rates of MB (2.50% vs 1.00%; P=0.001), ICH (1.42% vs 0.27%; P<0.0001), haemorrhagic stroke (1.42% vs 0.20%; P<0.0001), CRNMB (2.49% vs 1.40%; P=0.04), and any bleeding (7.57% vs 4.27%; P=0.001), but these rates were low compared to other high-risk populations. ICH was not selected as a predictor of cardiovascular outcomes on multivariate prediction modelling. ICH had non-significant effects in predicting all-cause death (HR 1.22), ischemic stroke (HR 1.14), and major bleeding (HF 1.37) and repeat ICH (HR 1.94).
Conclusions
Patients with a history of ICH are a small, elderly, multimorbid subgroup of patients with AF. Treatment with the non-vitamin K antagonist oral anticoagulant edoxaban resulted in relatively low rates of major events.
Collapse
Affiliation(s)
- J Moser
- University Heart Centre Hamburg, Department of Cardiology, Hamburg, Germany
| | - M Unverdorben
- Daiichi Sankyo, Inc., Basking Ridge, United States of America
| | - CC Wang
- Linkou Chang Gung Memorial Hospital and Chang Gung University, Division of Cardiology, Department of Internal Medicine, Taoyuan, Taiwan
| | - B Bruggenjurgen
- Steinbeis-University, Institute for Health Economics, Berlin, Germany
| | - BC Lee
- Hallym University Sacred Heart Hospital, Department of Neurology, Anyang, Korea (Republic of)
| | - C Chen
- Daiichi Sankyo, Inc., Basking Ridge, United States of America
| | - L Pecen
- Institute of Computer Science ASCR, Prague, Czechia
| | - T Yamashita
- Cardiovascular Institute, Department of Cardiovascular Medicine, Tokyo, Japan
| | - R De Caterina
- University of Pisa, Department of Surgery, Medical, Molecular and Critical Area Pathology, Pisa, Italy
| | - P Kirchhof
- University Heart Centre Hamburg, Department of Cardiology, Hamburg, Germany
| |
Collapse
|
19
|
Rottner L, Schleberger R, Lemoine M, My I, Moser F, Moser J, Dinshaw L, Kirchhof P, Ouyang F, Rillig A, Metzner A, Reissmann B. Catheter ablation of the mitral isthmus line using the novel DiamondTemp ablation system: first experience using two different ablation protocols. Europace 2022. [DOI: 10.1093/europace/euac053.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Mitral ishmus ablation is an established approach to treat perimitral reentrant tachycardia, and is often performed as substrat modification in patients with persistent atrial fibrillation (AF). Bidirectional block of the mitral isthmus line (MIL) is still a great challenge using conventional ablation catheters, but is essential to prevent recurrence of atrial arrhythmia.
Recently, the novel DiamondTempTM (DT) ablation system was introduced and allows for high-power, short-duration ablation in a temperature-controlled mode. Its use during pulmonary vein isolation (PVI) using a recommended ablation setting with a catheter-tip temperature limit of 60°C, a temperature-controlled power of 50 W and an application duration of 10 sec has shown to be effective and safe. However, data on DT ablation settings for substrate modification, i.e., creation of linear lesions are lacking.
Aim
The aim of the present study was to evaluate acute efficacy and safety of the novel DT ablation system for bidirectional block of the MIL using two different protocols.
Methods
The study population comprised 14 patients [67±8 years, 10/14 male (71%)] suffering from persistent AF and/or atrial tachycardia who underwent catheter re-ablation with creation of a MIL using the DT ablation system. Ablation settings were a catheter-tip temperature limit of 60°C, a temperature-controlled power of 50 W with an application duration of either 10 sec (group A, n=7) or 20 sec (group B, n=7). Additional epicardial ablation from within the coronary sinus with a temperature limit of 60°C, a temperature-controlled power of 20 W and an application duration of 20 sec was performed, if bidirectional block could not be achieved with endocardial ablation only.
Results
Mean procedure and fluoroscopy time, and dose area product for group A and group B were 103±24 vs. 119±38 min, 12±5 vs. 13±4 min, and 572±270 vs. 537±202 cGycm, respectively. Bidirectional block of the MIL was achieved in 7/7 (100%) patients in group A and in 6/7 (86%) patients in group B. Additional epicardial ablation was required in 6/7 patients (86%) in group A and in 4/7 (57%) patients in group B. In group B, bidirectional block of the MIL required fewer endocardial (31±11 vs. 26±10 applications) as well as epicardial RF-applications (10±6 vs. 7±3 applications). Pericardial effusion without hemodynamic relevance occurred in 1/7 (14%) patients of group B. No further complications occurred.
Conclusion
Catheter ablation of the MIL using the novel DT ablation system is safe and associated with high acute efficacy. A lower number of RF-applications and a less frequent need for additional epicardial ablation was observed when applying longer RF-applications of 20 sec. Further analyses are warranted to confirm these findings.
Collapse
Affiliation(s)
- L Rottner
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - R Schleberger
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - M Lemoine
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - I My
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - F Moser
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - J Moser
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - L Dinshaw
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - P Kirchhof
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - F Ouyang
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - A Rillig
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - A Metzner
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - B Reissmann
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| |
Collapse
|
20
|
Rottner L, Moser F, Schleberger R, Moser J, My I, Lemoine M, Dinshaw L, Kirchhof P, Ouyang F, Reissmann B, Metzner A, Rillig A. Optimizing catheter ablation of atrial fibrillation by a novel wide-band dielectric imaging system: first experience on real-time wall thickness measurement. Europace 2022. [DOI: 10.1093/europace/euac053.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Conventional mapping systems do not provide wall-thickness data, which is, however, known to be a determinant of radiofrequency ablation lesion transmurality. KODEX-EPD is a novel open-platform system, which uses dielectric tissue properties to provide real-time, high-resolution cardiac images, tissue characteristics and wall-thickness measurement to guide ablation procedures.
Aim
The aim of this case series was to report on our first experiences with KODEX-EPD regarding estimation of myocardial wall-thickness during catheter ablation of atrial fibrillation (AF).
Methods
We retrospectively analyzed consecutive patients undergoing radiofrequency AF-ablation in combination with KODEX-EPD. A high-resolution image from the left atrium (LA) and the pulmonary veins (PV) was obtained prior to ablation using a spiral mapping catheter in conjunction with KODEX-EPD. Wall-viewer points were collected within the LA, the PVs and the left atrial appendage (LAA) using a standard radiofrequency non-contact force ablation catheter and analyzed for wall-thickness applying the latest KODEX-EPD software version (1.5.0, not yet commercially released). Wall-viewer points were divided into a total of 10 segments (PV ostia, anterior wall, posterior wall, LA roof, LA floor, LAA and PV carina, details see Figure 1) in order to characterize wall-thickness in respective areas.
Results
A total of 570 wall-viewer points in 5 patients were analyzed. Most of the wall-viewer points were collected at the PV ostia as well as along the posterior and anterior wall (449/570, 79%). Actual myocardial atrial thickness ranged from 1.6 to 3.9 mm. Thickest myocardial LA-tissue was measured at the anterior wall (median 3.1 mm) and thinnest at the LA-roof (median 2.2 mm). Figure 2 gives a detailed distribution of wall-thickness measurements at different sites in the LA and PVs.
Conclusion
Atrial wall thickness can be estimated in patients during AF ablation procedures using dielectric tissue properties. Further evaluation and validation of the method are needed to study its reliability and utility for clinical practice.
Collapse
Affiliation(s)
- L Rottner
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - F Moser
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - R Schleberger
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - J Moser
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - I My
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Lemoine
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - L Dinshaw
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - P Kirchhof
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - F Ouyang
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - B Reissmann
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Metzner
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Rillig
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
21
|
Eberlein J, Moser J, Zhong Z, Bailey KA, Hoang SM, Schultz AJ, Candelli A, Reijmers RM, Singleterry W. Cellular avidity as a novel biomarker for candidate selection of cell-based immunotherapies. The Journal of Immunology 2022. [DOI: 10.4049/jimmunol.208.supp.179.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Cellular immunotherapies are increasingly complex in design. Affinity readouts, i.e., the measurements of the strength of single receptor-ligand interactions, are frequently used to assess the binding of chimeric antigen receptors (CARs) or T cell receptors (TCRs) to their ligand. However, affinity is a poor predictor of effector function of the engineered downstream product. Therefore, new tools are needed to evaluate the binding strength of CAR and TCR-transgenic cells to their cognate targets in a more biologically relevant context.
Recent studies demonstrated the utility of measuring cellular avidity as a novel biomarker for identifying and developing potent and safe immunotherapies. Unlike affinity, cellular avidity is driven by the overall strength of dynamic surface interactions between effector cells and their targets by integrating receptor density, the sum of individual affinities, and engagement of the multitude of co-receptors within the immunological synapse.
Here, we show that increased specific avidity, i.e., TCRs with the strongest antigen binding and the lowest background, correlated with improved effector function both in vitro and in vivo. For CAR-T, higher cellular avidity was significantly correlated with improved tumor control in in vivo murine models, but also associated with toxicities in patients, suggesting fine-tuning of cell therapies to the desired avidity for ideal function is needed.
Collapse
|
22
|
Darabi S, Elliott A, Braxton DR, Zeng J, Hodges K, Poorman K, Swensen J, Shanthappa BU, Hinton JP, Gibney GT, Moser J, Phung T, Atkins MB, In GK, Korn WM, Eisenberg BL, Demeure MJ. Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions. Cancers (Basel) 2022; 14:cancers14061505. [PMID: 35326655 PMCID: PMC8946593 DOI: 10.3390/cancers14061505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2022] [Revised: 03/08/2022] [Accepted: 03/10/2022] [Indexed: 11/24/2022] Open
Abstract
Simple Summary Malignant melanoma is a complex disease that is estimated to claim over 7000 lives in the United States in 2021. Although recent advances in genomic technology have helped with the identification of driver variants, molecular studies and clinical trials have often focused on prevalent alterations, such as the BRAF-V600E mutation. With the inclusion of whole transcriptome sequencing, molecular profiling of melanomas has identified gene fusions and revealed gene expression profiles that are consistent with the activation of signaling pathways by common driver mutations. Patients harboring such fusions may benefit from currently approved targeted therapies and should be considered in the design of future clinical trials to further personalize treatments for patients with malignant melanoma. Abstract Invasive melanoma is the deadliest type of skin cancer, with 101,110 expected cases to be diagnosed in 2021. Recurrent BRAF and NRAS mutations are well documented in melanoma. Biologic implications of gene fusions and the efficacy of therapeutically targeting them remains unknown. Retrospective review of patient samples that underwent next-generation sequencing of the exons of 592 cancer-relevant genes and whole transcriptome sequencing for the detection of gene fusion events and gene expression profiling. Expression of PDL1 and ERK1/2 was assessed by immunohistochemistry (IHC). There were 33 (2.6%) cases with oncogenic fusions (14 novel), involving BRAF, RAF1, PRKCA, TERT, AXL, and FGFR3. MAPK pathway-associated genes were over-expressed in BRAF and RAF1 fusion-positive tumors in absence of other driver alterations. Increased expression in tumors with PRKCA and TERT fusions was concurrent with MAPK pathway alterations. For a subset of samples with available tissue, increased phosphorylation of ERK1/2 was observed in BRAF, RAF1, and PRKCA fusion-positive tumors. Oncogenic gene fusions are associated with transcriptional activation of the MAPK pathway, suggesting they could be therapeutic targets with available inhibitors. Additional analyses to fully characterize the oncogenic effects of these fusions may support biomarker driven clinical trials.
Collapse
Affiliation(s)
- Sourat Darabi
- Hoag Family Cancer Institute, Newport Beach, CA 92663, USA; (D.R.B.); (B.L.E.); (M.J.D.)
- Correspondence:
| | - Andrew Elliott
- Caris Life Sciences, Phoenix, AZ 85040, USA; (A.E.); (J.Z.); (K.H.); (K.P.); (J.S.); (B.U.S.); (J.P.H.); (W.M.K.)
| | - David R. Braxton
- Hoag Family Cancer Institute, Newport Beach, CA 92663, USA; (D.R.B.); (B.L.E.); (M.J.D.)
| | - Jia Zeng
- Caris Life Sciences, Phoenix, AZ 85040, USA; (A.E.); (J.Z.); (K.H.); (K.P.); (J.S.); (B.U.S.); (J.P.H.); (W.M.K.)
| | - Kurt Hodges
- Caris Life Sciences, Phoenix, AZ 85040, USA; (A.E.); (J.Z.); (K.H.); (K.P.); (J.S.); (B.U.S.); (J.P.H.); (W.M.K.)
| | - Kelsey Poorman
- Caris Life Sciences, Phoenix, AZ 85040, USA; (A.E.); (J.Z.); (K.H.); (K.P.); (J.S.); (B.U.S.); (J.P.H.); (W.M.K.)
| | - Jeff Swensen
- Caris Life Sciences, Phoenix, AZ 85040, USA; (A.E.); (J.Z.); (K.H.); (K.P.); (J.S.); (B.U.S.); (J.P.H.); (W.M.K.)
| | - Basavaraja U. Shanthappa
- Caris Life Sciences, Phoenix, AZ 85040, USA; (A.E.); (J.Z.); (K.H.); (K.P.); (J.S.); (B.U.S.); (J.P.H.); (W.M.K.)
| | - James P. Hinton
- Caris Life Sciences, Phoenix, AZ 85040, USA; (A.E.); (J.Z.); (K.H.); (K.P.); (J.S.); (B.U.S.); (J.P.H.); (W.M.K.)
| | - Geoffrey T. Gibney
- Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC 20007, USA; (G.T.G.); (M.B.A.)
| | - Justin Moser
- Honor Health Research Institute, Scottsdale, AZ 85258, USA;
| | - Thuy Phung
- Department of Pathology, University of South Alabama, Mobile, AL 36617, USA;
| | - Michael B. Atkins
- Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC 20007, USA; (G.T.G.); (M.B.A.)
| | - Gino K. In
- Division of Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA;
| | - Wolfgang M. Korn
- Caris Life Sciences, Phoenix, AZ 85040, USA; (A.E.); (J.Z.); (K.H.); (K.P.); (J.S.); (B.U.S.); (J.P.H.); (W.M.K.)
| | - Burton L. Eisenberg
- Hoag Family Cancer Institute, Newport Beach, CA 92663, USA; (D.R.B.); (B.L.E.); (M.J.D.)
- Division of Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA;
| | - Michael J. Demeure
- Hoag Family Cancer Institute, Newport Beach, CA 92663, USA; (D.R.B.); (B.L.E.); (M.J.D.)
- Translational Genomics Research Institution, Phoenix, AZ 85004, USA
| |
Collapse
|
23
|
Grubnic S, Hine J, Adam EJ, Patel J, Moser J, Phillips C, Webb P, Blanks R. COVID-19: using chest CT of major trauma patients to monitor and evaluate the second wave in London and the development of routine monitoring in practice. Clin Radiol 2021; 77:231-235. [PMID: 35022132 PMCID: PMC8673733 DOI: 10.1016/j.crad.2021.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2021] [Accepted: 12/10/2021] [Indexed: 11/12/2022]
Abstract
AIM To follow-up previous work evaluating incidental findings of COVID-19 signs on computed tomography (CT) images of major trauma patients to include the second wave prior to any major effects from vaccines. MATERIALS AND METHODS The study population included all patients admitted following major trauma between 1 January 2020 and 28 February 2021 with CT including the lungs (n=1776). Major trauma patients admitted pre-COVID-19 from alternate months from January 2019 to November 2019 comprised a control group (n=837). The assessing radiologists were blinded to the time period and used double reading in consensus to determine if the patient had signs of COVID-19. Lung appearances were classified as no evidence of COVID-19, minor signs, or major signs. RESULTS The method successfully tracked the second wave of the COVID-19 pandemic in London. The estimated population affected by the disease based on those with major signs was similar to estimates of the proportion of the population in London with antibodies (around 30% by end February 2021) and the total of major and minor signs produced a much higher figure of 68%, which may include all those with both antibody and just T-cell responses. CONCLUSIONS Incidental findings on CT from major trauma patients may provide a novel and sensitive way of tracking the virus. It is recommended that all major trauma units include a simple question on signs of COVID-19 to provide an early warning system for further waves.
Collapse
Affiliation(s)
- S Grubnic
- Department of Radiology, St George's Hospital, Blackshaw Road, London, SW17 0QT, UK
| | - J Hine
- Department of Radiology, St George's Hospital, Blackshaw Road, London, SW17 0QT, UK.
| | - E J Adam
- Department of Radiology, St George's Hospital, Blackshaw Road, London, SW17 0QT, UK
| | - J Patel
- Department of Radiology, St George's Hospital, Blackshaw Road, London, SW17 0QT, UK
| | - J Moser
- Department of Radiology, St George's Hospital, Blackshaw Road, London, SW17 0QT, UK
| | - C Phillips
- Department of Radiology, St George's Hospital, Blackshaw Road, London, SW17 0QT, UK
| | - P Webb
- Department of Radiology, St George's Hospital, Blackshaw Road, London, SW17 0QT, UK
| | - R Blanks
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Oxford, OX3 7LF, UK
| |
Collapse
|
24
|
El-Khoueiry A, Bullock A, Tsimberidou A, Mahadevan D, Wilky B, Twardowski P, Bockorny B, Moser J, Feliu WO, Grossman J, Rosenthal K, O’Day S, Gordon M. 479 AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results. J Immunother Cancer 2021. [DOI: 10.1136/jitc-2021-sitc2021.479] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
BackgroundAGEN1181 is a novel anti-CTLA-4 antibody with enhanced FcyR-dependent functionality, engineered to bind high and low binding alleles of FcyRIIIA, promoting superior T cell priming, memory responses, and depletion of intratumoral T regulatory cells. Further, AGEN1181 avoids complement recruitment, predictive of better tolerability. Here we report initial safety and efficacy findings from a phase I/Ib study of AGEN1181 as monotherapy and in combination with balstilimab (BAL; anti-PD-1).MethodsEligible patients (pts) had advanced solid tumors refractory to standard therapies. AGEN1181 was dosed Q3W (0.1–3 mg/kg) or Q6W (1–2 mg/kg) as monotherapy, or Q6W (0.1–2 mg/kg) in combination with BAL Q2W (3 mg/kg).ResultsAs of July 16th 2021, 102 pts received AGEN1181 (43 monotherapy, 59 combination). Median age, 63 years (29–83); 50.5% with ≥3 prior lines of therapy. MTD not yet reached with AGEN1181 dosing up to 3 mg/kg Q3W as monotherapy and 2 mg/kg in combination with BAL. The most common treatment-related adverse events (TRAEs) of any grade were fatigue (34.3%), diarrhea (32.4%), and nausea (19.6%) with grade ≥3 events in 21.6% (diarrhea/colitis, 11.8%, fatigue, 2.9%). Notably, no immune-related hypophysitis or pneumonitis has been observed. Discontinuation from AGEN1181 due to TRAEs occurred in 15% of pts. Grade 5 TRAEs occurred in two pts (colitis [chronic], intestinal perforation). The disease control rate in evaluable pts (completed ≥1 on-treatment scan) defined as best overall response of CR, PR, or SD ≥6 weeks was 48.1% for AGEN1181 monotherapy ≥1 mg/kg (1 CR, 3 PR, 9 SD) and 70% for combination (3 PR, 6 unconfirmed PR [uPR], 19 SD). Monotherapy responders include individual pts with MSS endometrial cancer (CR), PD-1-relapsed/refractory cervical cancer (PR), PD-1-relapsed/refractory melanoma (PR), and pancreatic cancer (PR). Enrollment is continuing in several disease expansion cohorts with combination therapy. For MSS CRC, 2 PR, 2 uPR, and 7 SD have been seen in 17 evaluable ≥1 mg/kg patients to date. In the ovarian cohort (n=6), 2 PRs and 3 SD are noted. Additional combination responders include one PR and uPR in MSS endometrial cancer, two uPRs in visceral angiosarcoma (uPRs) and one uPR in PD-1-relapsed/refractory NSCLC (uPR); the majority of the responses are recent and ongoing.ConclusionsAGEN1181 alone and in combination with BAL demonstrates favorable tolerability and compelling clinical activity, notably in poorly immunogenic tumor types and PD-1-refractory pts. These results underscore the significant potential of AGEN1181 to expand benefit of anti-CTLA-4 therapy to a broader patient population.Trial RegistrationNCT03860272Ethics ApprovalThe study obtained ethics approval at each participating center (UT Health Sciences Center at San Antonio, University of Colorado Cancer Center, St John’s Cancer Institute, and HonorHealth under WIRB Study number 1256391; USC Norris Comprehensive Cancer Center, Beth Israel Deaconess Medical Center, and MD Anderson Cancer Center, approval numbers HS19-00277, 19–132, and 140346, respectively). All patients provided written informed consent in accordance with federal, local, and institutional guidelines.
Collapse
|
25
|
Parry-Williams G, Obaid D, Miles C, Basu J, MacLachlan H, Moser J, Vlahos I, O'Driscoll J, Chis Ster I, Papadakis M, Tome Esteban MT, Sharma S. Determinants of high-risk coronary artery disease in ostensibly healthy male master endurance athletes. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Healthy male master endurance athletes have a greater prevalence of high coronary calcium (CAC) scores compared to healthy sedentary counterparts, and some demonstrate high-risk plaque features. A number of theories have been postulated but reasons remain unclear. Concurrently atherosclerotic coronary artery disease (CAD) is the most common cause of sudden cardiac death in male master athletes drawing much public and scientific interest and making this an important public health issue.
Purpose
To examine the relationship of age, resting systolic blood pressure (SBP), exercise dose and sporting discipline with high-risk CAD markers in male master endurance athletes.
Methods
A prospective study undertaken over 19 months evaluated 214 male master (40–65 years) endurance athletes, free from known cardiovascular risk factors, symptoms or relevant health conditions. Clinical evaluation included cardiopulmonary exercise test, resting blood pressure (BP) and coronary computed tomogram angiography (CCTA). CCTA assessed CAC score, significant stenosis, (>50%) and plaque vulnerability markers. Exercise dose was defined by years of endurance exercise and average MET-hours/week (lifetime exercise volume multiplied by the metabolic equivalent scores). Resting BP was the average of 3 consecutive supine measures after at least 5 minutes rest.
Results
Athletes (mean age 51, SD 70.1) exercised for minimum 6 hours/week (median 8.5) for a median of 15 years (2–26). Almost half (60.2%) were multi-endurance athletes i.e. any combination swimming, cycling and running. The remainder were runners (22.4%) and cyclists (15.4%). Median Framingham risk score 3.2% (1.8–5.8). The mean resting BP was 129/80 mmHg and a quarter (26%) of athletes were hypertensive (≥140/90 mmHg) at rest. A CAC score >100 Agatston units (AU) was present in 16% of athletes. There was a total of 15 stenotic lesions in 11 (5%) athletes. 13% had plaque vulnerability markers.
Logistic regression evaluated whether age, resting SBP, exercise dose measures and sporting discipline were predictive for a CAC score >100 AU, significant stenosis and plaque vulnerability markers (table 1). CAC score was associated with age, years of endurance exercise and resting SBP. A Stenosis >50% and plaque vulnerability markers were associated with resting SBP and cycling compared with all other sporting disciplines.
Conclusion
Despite correcting for age, higher exercise dose (years endurance exercise) is associated with CAC score >100 AU but does not predict significant stenosis or plaque vulnerability markers. Resting SBP and cycling strongly predict high-risk disease. Cycling enables a greater intensity of exercise compared with other endurance sports, which may be associated with prolonged rises in SBP. Resting SBP and cycling are important determinants for high-risk CAD in middle-aged male endurance athletes and should be considered when risk stratifying in pre-participation evaluation.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): British Heart Foundation Clinical Research Training Fellowship
Collapse
Affiliation(s)
- G Parry-Williams
- St George's University of London, Molecular and Clinical Sciences Research, London, United Kingdom
| | - D Obaid
- Swansea University, Swansea, United Kingdom
| | - C Miles
- St George's University of London, Molecular and Clinical Sciences Research, London, United Kingdom
| | - J Basu
- St George's University of London, Molecular and Clinical Sciences Research, London, United Kingdom
| | - H MacLachlan
- St George's University of London, Molecular and Clinical Sciences Research, London, United Kingdom
| | - J Moser
- St George's Healthcare NHS Trust, London, United Kingdom
| | - I Vlahos
- University of Texas MD Anderson Cancer Centre, Houston, United States of America
| | - J O'Driscoll
- Canterbury Christ Church University, Canterbury, United Kingdom
| | - I Chis Ster
- St George's University of London, London, United Kingdom
| | - M Papadakis
- St George's University of London, Molecular and Clinical Sciences Research, London, United Kingdom
| | - M T Tome Esteban
- St George's University of London, Molecular and Clinical Sciences Research, London, United Kingdom
| | - S Sharma
- St George's University of London, Molecular and Clinical Sciences Research, London, United Kingdom
| |
Collapse
|
26
|
Rottner L, Moser F, Schleberger R, Weimann J, Moser J, Lemoine M, Muenkler P, Dinshaw L, Risius T, Kirchhof P, Ouyang F, Reissmann B, Metzner A, Rillig A. Accuracy and acute efficacy of a novel occlusion tool to guide cryoballoon-based pulmonary vein isolation. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Cryoballoon (CB)-based pulmonary vein isolation (PVI) currently requires to verify occlusion of each pulmonary vein (PV) using fluoroscopy and dye injection.
Objective
The current study evaluated whether the novel CB-occlusion tool integrated into the wide-band dielectric imaging system KODEX-EPD reliably verifies occlusion of PV according to a novel dye-injection based algorithm.
Methods
Consecutive patients suffering from symptomatic atrial fibrillation (AF) underwent CB-based PVI using the KODEX-EPD and the novel occlusion-tool (group I). To confirm accurate display of the PVs, selective PV-angiography was performed in the first half of the patients of group I (group Ia) in addition to a three-dimensional left atrial (LA) map using a spiral mapping catheter (Achieve, SMC1, Medtronic, MN, USA). PV-angiographies were waived for the following patients (group Ib). Procedural duration and radiation exposure were compared to a control group of patients undergoing conventional CB-based PVI.
Results
CB-based PVI was successful in 50/50 patients of group I (mean age 63±11 years, 18 paroxysmal (36%)) and 25/25 patients of group II (66±10 years, 9 paroxysmal (60%)). Concordance of PV-occlusion as assessed by either PV-occlusion-angiography or KODEX-EPD, was documented in 237/272 (87%) occlusion-analyses among 198 PVs (95% for left superior PV, 93% for left inferior PV, 86% for right inferior PV and 77% for right superior PV).
In the final evaluation phase (group Ib) LA fluoroscopy times and dose area products were comparable to the conventional CB-ablation group (10.5±5 vs 8.8±4 minutes (p=0.23) and 403±425 vs 321±202 cGycm2 (p=0.44), whereas the amount of dye could be significantly reduced (group Ib: 31±10 ml vs group II: 70±20 ml, p<0.0001).
Conclusion
The novel KODEX-EPD PV-occlusion tool allows for accurate PV-occlusion assessment in the majority of PVs and a high acute success rate. The system has the potential to reduce dye and radiation exposure. This should be evaluated in controlled clinical trials.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- L Rottner
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - F Moser
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - R Schleberger
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - J Weimann
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - J Moser
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - M Lemoine
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - P Muenkler
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - L Dinshaw
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - T Risius
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - P Kirchhof
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - F Ouyang
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - B Reissmann
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - A Metzner
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - A Rillig
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| |
Collapse
|
27
|
Tolcher A, Babiker HM, Chung V, Kim E, Moser J, Karim R, Vandross A, Sommerhalder D, Scott AJ, Fakih M, Massarelli E, Adams J, Stewart J, Bossard C, Do L, White M, Beaupre DM, Borazanci E. Abstract CT112: Initial results from a Phase 1 trial of a first-in-class pan-CDC-like kinase inhibitor (SM08502) with proof of mechanism in subjects with advanced solid tumors. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-ct112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Dysregulation of alternative pre-mRNA splicing has been identified as a common mechanistic driver of tumor initiation, disease progression, and emergence of therapy resistance. An iterative screening campaign identified SM08502, a potent pan-inhibitor of CDC-like kinases (CLKs), which are known to regulate alternative splicing. In preclinical studies, SM08502 inhibited growth and induced apoptosis in a broad array of tumor models. Study NCT03355066 is a two-part Phase 1 first-in-human study that evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered SM08502 in subjects with advanced solid tumors. In Part 1A of the study, which utilized an accelerated-titration/3 + 3 dose-escalation design, 19 subjects were administered SM08502 at doses ranging from 10 mg to 80 mg; a maximum tolerated dose has not yet been identified. Systemic exposures showed dose-dependent increases from 10 mg to 80 mg and the mean time to maximal concentration (tmax) ranged from 3.3 to 5.9 hours on Cycle 1 Day 1 and from 1 to 24.6 hours on Cycle 2 Day 1. SM08502 had low-to-moderate clearance and a high volume of distribution, which resulted in a long terminal half-life (t½ > 24 hours) and accumulation of approximately 2- to 3.9-fold. Based on preclinical tumor xenograft models, exposures (AUC and Cmax) in the expected therapeutic range were attained. The most commonly reported adverse events (AEs) included nausea (12/19 [63.2%]), diarrhea (10/19 [52.6%]), fatigue (8/19 [42.1%]), and vomiting (7/19 [36.8%]), with the most common grade 3 or greater AEs being diarrhea (3/19 [15.8%]), anemia (2/19 [10.5%]), and decreased lymphocyte count (2/19 [10.5%]). The most common possibly or probably related serious AE (SAE) was diarrhea (2/19 [10.5%]). Two subjects experienced dose-limiting toxicity: one at the 40 mg dose level (elevated liver function tests [ALT and AST]) and a second at the 80 mg dose level (diarrhea). In peripheral blood mononuclear cells, evidence for disruption of alternative splicing was detected through expression changes associated with mRNA splicing and nonsense-mediated decay. Further, direct evidence for CLK1 inhibition was observed at tolerated doses, which provided proof of mechanism. Radiological assessment demonstrated tumor shrinkage in two subjects with endometrial cancer. In addition, stable disease lasting longer than 6 months was observed in four subjects. Further dose finding is planned prior to the Part 2 expansion.
Conclusion: In this first-in-human study, PK and PD data demonstrate proof of mechanism for the pan-CLK inhibitor SM08502 at tolerated doses.
Citation Format: Anthony Tolcher, Hani M. Babiker, Vincent Chung, Edward Kim, Justin Moser, Raghad Karim, Andre Vandross, David Sommerhalder, Aaron J. Scott, Marwan Fakih, Erminia Massarelli, Jeffrey Adams, Joshua Stewart, Carine Bossard, Long Do, Michael White, Darrin M. Beaupre, Erkut Borazanci. Initial results from a Phase 1 trial of a first-in-class pan-CDC-like kinase inhibitor (SM08502) with proof of mechanism in subjects with advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT112.
Collapse
Affiliation(s)
| | | | | | | | - Justin Moser
- 5HonorHealth Research and Innovation Institute, Scottsdale, AZ
| | | | | | | | | | | | | | | | | | | | - Long Do
- 6Samumed, LLC, San Diego, CA
| | | | | | - Erkut Borazanci
- 5HonorHealth Research and Innovation Institute, Scottsdale, AZ
| |
Collapse
|
28
|
Drenner K, Srivastava S, Halder K, Basu G, Halder TG, Prabhu A, Ampanattu SD, de Villar RR, Weston A, Thode T, Royce T, Kaadige M, Moser J, Guarnieri C, Steinbach M, Richards J, Tsai F, Sachdev J, Borazanci E, Gordon M, Trent J, Soldi R, Sharma S. Abstract 4404: PAThway based RNA and DNA Integration with tumor Organoid Testing for clinical therapeutics (PATRIOT). Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-4404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Whole genome sequencing is utilized in the clinic with limited benefit. Only a fraction of patients sequenced will have a driver mutation that can be targeted by a drug. Treating with a targeted therapy often demonstrates a response but ultimately, resistance results in progression. Many of the common mutations, like KRAS, are currently not targetable and are only used to predict poor prognosis. The narrow clinical therapeutic potential of DNA sequencing shows a need for integration of other analyses like RNA and proteomics. RNA sequencing is currently used by some CLIA certified clinical reports to identify novel fusions in patient data but has not been completely integrated into the clinic. The primary roadblocks for complete RNA sequencing integration are due to batch effect, proper control tissue selection, tumor purity, and false positives or negatives. In this study we investigated the utility of using a cohort of normal control samples for Differential Expression (DE) analysis and the ability of RNA and DNA integration to identify new therapeutic targets (PATRIOT). This study also implements the use of patient-derived tumor organoids to test and validate the therapeutic targets using multi-omic analysis.
Experimental Design: PATRIOT utilizes sequencing from 22 different normal tissue controls. The cut off for significant gene expression is a fold change greater than 1.5 in 50 percent of the controls and a standard deviation less than the fold change. Top 1000 overexpressed and top 1000 underexpressed genes were input into Qiagen's Ingenuity Pathway Analysis (IPA) to identify canonical pathways, upstream regulators, and causal networks. Literature searches identified potential single and combination drugs to use on the tumor organoids. Organoids were generated by dissociating the patient tumor sample and immortalizing the primary cells using hTERT. Drug dosing on organoids was performed using a 6 point 4 fold dilution. IC50 was calculated using Graphpad PRISM and synergy was calculated using Calcusyn.
Results: PATRIOT analysis identified potential therapeutic targets, aberrant pathways, and ranked targetable mutations. These drugable targets were validated on the tumor organoids. Organoids were successfully generated with limited tissue in a therapeutic window. In a melanoma patient with an IDH1(R132C) and NRAS(Q61L) mutation, PATRIOT analysis predicted inactivation of NRAS and also predicted IDH1 mutation induced reduction of expression of DNA damage repair genes. The tumor organoids showed limited response to Trametinib and Everolimus while Olaparib exhibited a large response.
Conclusion: Our data suggests that PATRIOT analysis using a cohort of normal control samples can generate reliable DE data. PATRIOT methodology could expand the therapeutic potential for patients with direct in vitro results.
This study was supported by funding from Flinn Foundation grant #2193.
Citation Format: Kevin Drenner, Shreyesi Srivastava, Kuntal Halder, Gargi Basu, Tithi Ghosh Halder, Abishta Prabhu, Sherin Daniel Ampanattu, Ryan Rodriguez de Villar, Alexis Weston, Trason Thode, Tom Royce, Mohan Kaadige, Justin Moser, Carol Guarnieri, Margaux Steinbach, Jacqueline Richards, Frank Tsai, Jasgit Sachdev, Erkut Borazanci, Michael Gordon, Jeffery Trent, Raffaella Soldi, Sunil Sharma. PAThway based RNA and DNA Integration with tumor Organoid Testing for clinical therapeutics (PATRIOT) [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4404.
Collapse
Affiliation(s)
- Kevin Drenner
- 1Translational Genomics Research Institute (TGen), Phoenix, AZ
| | | | | | - Gargi Basu
- 3Ashion TGen Clinical Laboratory, Phoenix, AZ
| | | | - Abishta Prabhu
- 1Translational Genomics Research Institute (TGen), Phoenix, AZ
| | | | | | - Alexis Weston
- 1Translational Genomics Research Institute (TGen), Phoenix, AZ
| | - Trason Thode
- 1Translational Genomics Research Institute (TGen), Phoenix, AZ
| | - Tom Royce
- 3Ashion TGen Clinical Laboratory, Phoenix, AZ
| | - Mohan Kaadige
- 1Translational Genomics Research Institute (TGen), Phoenix, AZ
| | | | | | | | | | - Frank Tsai
- 2HonorHealth Research Institute, Phoenix, AZ
| | | | | | | | - Jeffery Trent
- 1Translational Genomics Research Institute (TGen), Phoenix, AZ
| | - Raffaella Soldi
- 1Translational Genomics Research Institute (TGen), Phoenix, AZ
| | - Sunil Sharma
- 1Translational Genomics Research Institute (TGen), Phoenix, AZ
| |
Collapse
|
29
|
Matrana MR, Tsai F, Cleary JM, Satti S, Borazanci E, Estes J, Moser J, Do KT, Du L, Sharma S, Khemka V, Kolmakov V, Kawabe T, Shapiro G. Phase Ib clinical study of CBP501, cisplatin, and nivolumab administered every three weeks in patients with advanced refractory tumors: Efficacy in dose-escalation and expansion cohorts. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.3059] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3059 Background: CBP501 is a 12-amino acid G2 checkpoint abrogator and calmodulin-modulating peptide that increases platinum influx into tumor cells and induces tumor immunogenic cell death. CBP501 also suppresses platinum-induced release of cytokines by macrophages, lowers cancer stem cell populations, and reduces migration, invasion, and epithelial-mesenchymal transition of tumor cells. We report safety and efficacy outcomes from dose-escalation and expansion cohorts of a Phase Ib study of CBP501 combined with cisplatin and nivolumab (NCT03113188). Methods: An open-label Phase I trial was conducted using a 3+3 design: CBP501 and cisplatin were dosed simultaneously by 1h infusion Q3W at 4 different combined dose levels (CBP501: 16 or 25 mg/m2; cisplatin: 60 or 75 mg/m2) in the dose-escalation cohort. Nivolumab (240 mg) was dosed on the same day as a 1h infusion following CBP501/cisplatin. CBP501 and cisplatin were fixed at 25 and 60 mg/m2, respectively, in the expansion cohort. Eligible patients had pathologically confirmed, locally advanced or metastatic solid tumors, age ≥18 years, ECOG PS 0-1, life expectancy > 3 months. The dose-expansion cohort had pretreated metastatic exocrine pancreatic cancer or microsatellite stable colorectal cancer (CRC). Scans were performed every 6 weeks while on study, then every 3 months. Results: The most common related adverse events (AEs) were infusion-related reaction (rash, itching, hives; n = 32/37 [Gr 1, n = 4; Gr 2, n = 28]; 86%) and anemia (n = 19/37 [Gr 1/2, n = 10; Gr 3, n = 9]; 51%). There were no additional safety signals other than those known for each agent. At January 9, 2020 (interim analysis), efficacy was evaluable in 17/19 patients in the dose-escalation cohort. Unconfirmed partial response was seen in 18% (3/17; 1 pancreatic, 1 colorectal, 1 cholangiocarcinoma), with > 3 months stable disease (SD) in 41% (7/17), disease control in 41% (7/17), and > 8 months overall survival (OS) in 53% (9/17). In the expansion cohort, efficacy was evaluable in 8/13 patients with pancreatic cancer: > 4 months SD was 50% (4/8), median progression-free survival 4.2 months, and median OS 5.9 months (6/8 ≥3rd line). The CRC cohort median OS for all CRC patients (n = 10) including the dose-escalation cohort (n = 5) was 17.5 months (10/10 ≥3rd line). Conclusions: The triple-drug combination is reasonably tolerable with preliminary signs of efficacy in refractory solid tumors, including those in which cisplatin and nivolumab have limited single-agent activity. Clinical trial information: NCT03113188 .
Collapse
Affiliation(s)
| | | | | | | | | | | | - Justin Moser
- University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| | - Khanh Tu Do
- Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA
| | | | - Sunil Sharma
- Translational Genomics Research Institute (TGen), Phoenix, AZ
| | | | | | | | | |
Collapse
|
30
|
Abstract
Time-lapse imaging reveals a nuanced role for p21 in cancer cells challenged with chemotherapeutic drugs: cells with either high or low p21 are biased toward senescence, whereas intermediate p21 allows cells to re-enter the cell cycle after drug treatment.
Collapse
Affiliation(s)
- Humza M Ashraf
- Department of Biochemistry and BioFrontiers Institute, University of Colorado Boulder, Boulder, CO, USA
| | - Justin Moser
- Department of Biochemistry and BioFrontiers Institute, University of Colorado Boulder, Boulder, CO, USA
| | - Sabrina L Spencer
- Department of Biochemistry and BioFrontiers Institute, University of Colorado Boulder, Boulder, CO, USA.
| |
Collapse
|
31
|
Baron K, Nevala-Plagemann CD, Moser J, Haaland B, Wang X, Garrido-Laguna I. Survival outcomes based on sequence of therapy using FOLFIRINOX and nab-paclitaxel + gemcitabine in metastatic pancreatic ductal adenocarcinoma. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.4_suppl.657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
657 Background: Optimal sequence of therapy for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) is unknown. FOLFIRINOX (FFX) and Gemcitabine + Nab-paclitaxel (AG) are standard first line (1L) therapies. They have never been prospectively compared. Therefore, we retrospectively compared the overall survival (OS) of patients treated with 1L AG and second line (2L) FFX compared to those treated with 1L FFX and 2L AG. Methods: Patients with mPDAC treated with 1L FFX followed by 2L AG, or vice versa were identified using the Flatiron Health EHR-derived nationwide database. To avoid immortal time bias, patients who received no 2L were included. OS from the initiation of 1L was compared with Kaplan Meier curves and log rank analysis. A cox model, stratified by deciles of propensity score (PS), was used to estimate the effect of treatment on OS with adjustment for differences between the groups. Results: 3,042 patients were identified. 2001 patients received 1L AG. Among these patients, 1446 received 2L FFX, and 555 received no 2L. 1041 patients received 1L FFX. Among these patients, 496 received 2L AG, and 545 received no 2L. Median OS and 1-year OS for those treated with 1L AG followed by 2L FFX or no therapy was 6.1 months (95% CI:5.6 – 6.5) and 25% (95% CI: 0.23 – 0.28). Median OS and 1-year OS for patients treated with 1L FFX followed by AG or no therapy was 8.7 months (95% CI: 7.9 – 9.2) and 36% (95% CI: 0.33 – 0.39). The propensity stratified hazard ratio between these two groups was 0.76 (95% CI: 0.69 – 0.83), favoring 1L FFX. Median OS for patients treated with 1L FFX and 2L AG versus 1L AG and 2L FFX was not significantly different (12.0 m vs. 12.5 m; HR 1.04; 95% CI: 0.90 - 1.20). Conclusions: In this analysis of real-world data, 1L FFX was associated with increased OS in propensity analysis. For patients who received both FFX and AG, median OS was similar, regardless of the sequence.
Collapse
Affiliation(s)
- Kelsey Baron
- Division of Internal Medicine, Intermountain Medical Center, Murray, UT
| | | | | | - Benjamin Haaland
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | | | | |
Collapse
|
32
|
Soo E, Edey A, Mak S, Moser J, Mohammadi S, Rodrigues T, Duffy S, Field J, Baldwin D, Nair A, Devaraj A. Impact of choice of volumetry software and nodule management guidelines on recall rates in lung cancer screening. Eur J Radiol 2019; 120:108646. [DOI: 10.1016/j.ejrad.2019.108646] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2019] [Revised: 08/07/2019] [Accepted: 08/30/2019] [Indexed: 11/15/2022]
|
33
|
Moser J, Wei G, Colonna S, Grossmann K, Patel S, Hyngstrom J. Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I. Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO Open 2019; 4:e000539. [PMID: 31423338 PMCID: PMC6677976 DOI: 10.1136/esmoopen-2019-000539] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Revised: 06/20/2019] [Accepted: 06/22/2019] [Indexed: 12/16/2022] Open
Abstract
Background The role of continuing anti-HER2 therapy beyond progression on front-line therapy in patients with metastatic HER2 positive gastro-oesophageal cancer (GEC) is unclear. Continued chemotherapy plus trastuzumab (CT) has never been compared with the current standard second-line treatment, chemotherapy plus ramucirumab (CR). Methods The Flatiron Health electronic health record derived database, a nationwide database comprising patient-level structured and unstructured data, curated via technology-enabled abstraction, was reviewed for patients with metastatic HER2 positive GEC who received first-line CT, followed by second-line CT or CR. Survival from second-line therapy (SST) and time to next therapy or death (TTNTD) were compared using Kaplan-Meier curves and logrank analysis. Results 133 patients with metastatic HER2 positive GEC who received first-line CT were identified. 32 received second-line CR and 101 received CT. Median SST for patients treated with CT versus CR was 10.2 months (IQR 5.1–20.8) and 6.8 months (IQR 2.4–20.2), respectively (p=0.29). Median TTNTD for second-line CT versus CR was 4.9 months (IQR 2.8–9.8) and 5.1 months (IQR 2.3–7.5), respectively (p=0.65). Patients who received second-line CT were more likely to receive a multiagent chemotherapy backbone (76% vs 3%, p≤0.001). Conclusions This analysis showed no significant difference in SST for patients treated with second-line CT versus CR. Further studies are needed to clarify the role of trastuzumab in the second line, especially in patients with confirmed retention of HER2 positivity following progression.
Collapse
Affiliation(s)
| | - Justin Moser
- Oncology, Huntsman Cancer Institute, Salt Lake City, Utah, USA
| | | | | |
Collapse
|
35
|
Lee YC, McNevin M, Ikeda C, Chouzouri G, Moser J, Harris D, Howell L. Combination of Colloidal Silicon Dioxide with Spray-Dried Solid Dispersion to Facilitate Discharge from an Agitated Dryer. AAPS PharmSciTech 2019; 20:182. [PMID: 31054050 DOI: 10.1208/s12249-019-1392-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Accepted: 04/09/2019] [Indexed: 02/01/2023] Open
Abstract
A feasibility evaluation of the addition of fumed silica (SiO2) into an agitated dryer to aid spray-dried solid dispersion intermediate (SDSDi) flow during secondary drying and discharge is described. The quantity of SiO2 to enhance the flow character of SDSDi was assessed by measuring particle size distribution, bulk density, and flow-through-an-orifice. Results indicate that the addition of the SiO2 did not alter the drying kinetics and did not impact the bulk particle size distribution of the SDSDi. While bulk density of SDSDi increased with the addition of SiO2, the flow, and thus the recovery of the SDSDi-SiO2 batch from the secondary dryer, was significantly higher than that for the intermediate alone. Imaging indicated uniform distribution of SiO2 in the bulk powder and coating on intermediate particles. Premixing and co-sieving of the SiO2 with a portion of pre-dry SDSDi promotes the uniform distribution of SiO2 within the bulk powder bed.
Collapse
|
36
|
Hunter L, Moser J, Sturge C, Barraza G, Colonna S. First-line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: A case report. J Oncol Pharm Pract 2019; 26:216-219. [PMID: 30832555 DOI: 10.1177/1078155219835006] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Plasmacytoid urothelial carcinoma (PUC) is a rare but aggressive variant of transitional cell carcinoma. In patients with unresectable disease, cisplatin-based combination chemotherapy is the most commonly used treatment. However, many patients are cisplatin-ineligible due to poor performance status or other comorbidities. We report a case of a cisplatin-ineligible patient with metastatic PUC who was treated with pembrolizumab. CASE REPORT A 71-year-old man with 30 pack-year smoking history and schizoaffective disorder was found to have multiple right-sided lung nodules after presenting with atypical chest pain. Staging CT showed bilateral adrenal masses and a large soft tissue mass in the right iliac fossa. Tissue pathology and immunohistochemical staining was consistent with PUC. As the patient was cisplatin-ineligible due to poor performance status and multiple medical comorbidities, the decision was made to treat with pembrolizumab. Repeat CT chest and abdomen showed partial response at three months and stable disease at six months. DISCUSSION The KEYNOTE-052 study found that first-line pembrolizumab in cisplatin-ineligible patients with urothelial cancer resulted in complete or partial response in 24% of patients with few adverse effects. However, it is unclear if patients with plasmacytoid variant were included. To our knowledge, this is the first case report of a patient with metastatic PUC not only treated with pembrolizumab but shown to have clinical response. CONCLUSION Given our patient's clinical response, pembrolizumab is a promising first-line agent for treating cisplatin-ineligible patients with metastatic PUC. Further evaluation is warranted to confirm the benefit of treating this patient population with pembrolizumab.
Collapse
Affiliation(s)
- Lindsay Hunter
- Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA
| | - Justin Moser
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
| | - Caleb Sturge
- Department of Radiology, University of Utah, Salt Lake City, UT, USA
| | - Gonzalo Barraza
- George E Wahlen Department of Veterans Affairs Medical Center, Department of Pathology, Salt Lake City, UT, USA
| | - Sarah Colonna
- Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.,Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.,George E Wahlen Department of Veterans Affairs Medical Center, Division of Hematology and Oncology, Salt Lake City, UT, USA
| |
Collapse
|
37
|
Moser J, Solomon B, Nevala-Plagemann CD, Gilcrease GW, Whisenant JR, Garrido-Laguna I. Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.4_suppl.69] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
69 Background: Optimal second line treatment for patients with metastatic HER2 positive gastroesophageal cancer (Her2GE) is unknown. A retrospective study has suggested continuation of chemotherapy with trastuzumab (CT), as compared to chemotherapy alone, may improve outcomes. However, CT has never been compared to the current standard second-line treatment of chemotherapy plus ramucirumab (CR). Methods: The Flatiron Health EHR-derived database, a nationally representative database comprising patient-level structured and unstructured data, curated via technology-enabled abstraction, was reviewed for patients with metastatic Her2GE who received CT in the first line setting, followed by either second line CT or CR. Survival from second line therapy (SST) and time to next therapy or death (TTNTD) were compared using Kaplan-Meier curves and Log-Rank analysis. Demographics between treatment groups were compared using standard T tests and chi-squared analysis. Results: 135 patients were identified, of whom 34 received second-line CR and 101 received CT. Median SST for patients treated with CT was 10.2 months (m) [interquartile range (IQR) 5.1-20.8] and 6.8 m (IQR 3.2-20.2) for those treated with CR, p = 0.39. Median TTNTD for patients treated with CT versus CR was 4.9 m (IQR 2.8-9.8) and 4.8 m (IQR 2.3-7.5), respectively (p = 0.53). There was no difference between patients who received CT or CR in regards to average age (63 vs. 62, p = 0.72), average duration of first-line therapy (7.8 m vs. 9.1 m, p = 0.36), or percentage of patients with ECOG > 1 (15% vs. 22%, p = 0.50). Patients who received CT were more likely to receive a multiagent chemotherapy backbone (76% vs. 3%, p ≤ 0.001). Conclusions: This data suggest a non-significant trend towards increased SST for patients treated with second line CT versus CR. Further studies are needed to clarify optimal second-line treatment for this patient population.
Collapse
Affiliation(s)
- Justin Moser
- University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| | - Benjamin Solomon
- University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| | | | | | | | | |
Collapse
|
38
|
Abstract
The Restriction Point was originally defined as the moment that cells commit to the cell cycle and was later suggested to coincide with hyperphosphorylation of the retinoblastoma protein (Rb). Current cell cycle models posit that cells exit mitosis into a pre-Restriction Point state, where they have low cyclin-dependent kinase (CDK) activity and hypophosphorylated Rb; passage through the Restriction Point then occurs in late G1. Recent single-cell studies have challenged the current paradigm, raising questions about the location of the Restriction Point and the notion that cells exit mitosis into a pre-Restriction Point state. Here, we use a variety of single-cell techniques to show that both noncancer and cancer cells bifurcate into two subpopulations after anaphase, marked by increasing vs. low CDK2 activity and hyper- vs. hypophosphorylation of Rb. Notably, subpopulations with hyper- and hypophosphorylated Rb are present within minutes after anaphase, delineating one subpopulation that never "uncrosses" the Restriction Point and continues cycling and another subpopulation that exits mitosis into an uncommitted pre-Restriction Point state. We further show that the CDK inhibitor p21 begins rising in G2 in mother cells whose daughters exit mitosis into the pre-Restriction Point, CDK2low state. Furthermore, degradation of p21 coincides with escape from the CDK2low state and passage through the Restriction Point. Together, these data support a model in which only a subset of cells returns to a pre-Restriction Point state after mitosis and where the Restriction Point is sensitive to not only mitogens, but also inherited DNA replication stress via p21.
Collapse
Affiliation(s)
- Justin Moser
- Department of Biochemistry, University of Colorado-Boulder, Boulder, CO 80303
- BioFrontiers Institute, University of Colorado-Boulder, Boulder, CO 80309
| | - Iain Miller
- Department of Biochemistry, University of Colorado-Boulder, Boulder, CO 80303
- BioFrontiers Institute, University of Colorado-Boulder, Boulder, CO 80309
| | - Dylan Carter
- Department of Biochemistry, University of Colorado-Boulder, Boulder, CO 80303
- BioFrontiers Institute, University of Colorado-Boulder, Boulder, CO 80309
| | - Sabrina L Spencer
- Department of Biochemistry, University of Colorado-Boulder, Boulder, CO 80303;
- BioFrontiers Institute, University of Colorado-Boulder, Boulder, CO 80309
| |
Collapse
|
39
|
Arora M, Moser J, Phadke H, Basha AA, Spencer SL. Endogenous Replication Stress in Mother Cells Leads to Quiescence of Daughter Cells. Cell Rep 2018; 19:1351-1364. [PMID: 28514656 DOI: 10.1016/j.celrep.2017.04.055] [Citation(s) in RCA: 109] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Revised: 03/23/2017] [Accepted: 04/19/2017] [Indexed: 12/17/2022] Open
Abstract
Mammalian cells have two fundamentally different states, proliferative and quiescent, but our understanding of how and why cells switch between these states is limited. We previously showed that actively proliferating populations contain a subpopulation that enters quiescence (G0) in an apparently stochastic manner. Using single-cell time-lapse imaging of CDK2 activity and DNA damage, we now show that unresolved endogenous replication stress in the previous (mother) cell cycle prompts p21-dependent entry of daughter cells into quiescence immediately after mitosis. Furthermore, the amount of time daughter cells spend in quiescence is correlated with the extent of inherited damage. Our study thus links replication errors in one cell cycle to the fate of daughter cells in the subsequent cell cycle. More broadly, this work reveals that entry into quiescence is not purely stochastic but has a strong deterministic component arising from a memory of events that occurred in the previous generation(s).
Collapse
Affiliation(s)
- Mansi Arora
- Department of Chemistry and Biochemistry, University of Colorado Boulder, Boulder, CO 80309, USA
| | - Justin Moser
- Department of Chemistry and Biochemistry, University of Colorado Boulder, Boulder, CO 80309, USA
| | - Harsha Phadke
- Department of Electrical, Computer and Energy Engineering, University of Colorado Boulder, Boulder, CO 80309, USA
| | - Ashik Akbar Basha
- Department of Electrical, Computer and Energy Engineering, University of Colorado Boulder, Boulder, CO 80309, USA
| | - Sabrina L Spencer
- Department of Chemistry and Biochemistry, University of Colorado Boulder, Boulder, CO 80309, USA.
| |
Collapse
|
40
|
Gookin S, Min M, Phadke H, Chung M, Moser J, Miller I, Carter D, Spencer SL. A map of protein dynamics during cell-cycle progression and cell-cycle exit. PLoS Biol 2017; 15:e2003268. [PMID: 28892491 PMCID: PMC5608403 DOI: 10.1371/journal.pbio.2003268] [Citation(s) in RCA: 66] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2017] [Revised: 09/21/2017] [Accepted: 08/22/2017] [Indexed: 12/31/2022] Open
Abstract
The cell-cycle field has identified the core regulators that drive the cell cycle, but we do not have a clear map of the dynamics of these regulators during cell-cycle progression versus cell-cycle exit. Here we use single-cell time-lapse microscopy of Cyclin-Dependent Kinase 2 (CDK2) activity followed by endpoint immunofluorescence and computational cell synchronization to determine the temporal dynamics of key cell-cycle proteins in asynchronously cycling human cells. We identify several unexpected patterns for core cell-cycle proteins in actively proliferating (CDK2-increasing) versus spontaneously quiescent (CDK2-low) cells, including Cyclin D1, the levels of which we find to be higher in spontaneously quiescent versus proliferating cells. We also identify proteins with concentrations that steadily increase or decrease the longer cells are in quiescence, suggesting the existence of a continuum of quiescence depths. Our single-cell measurements thus provide a rich resource for the field by characterizing protein dynamics during proliferation versus quiescence.
Collapse
Affiliation(s)
- Sara Gookin
- Department of Chemistry and Biochemistry, University of Colorado-Boulder, Boulder, Colorado, United States of America
| | - Mingwei Min
- Department of Chemistry and Biochemistry, University of Colorado-Boulder, Boulder, Colorado, United States of America
| | - Harsha Phadke
- Department of Electrical, Computer & Energy Engineering, University of Colorado-Boulder, Boulder, Colorado, United States of America
| | - Mingyu Chung
- Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California, United States of America
| | - Justin Moser
- Department of Chemistry and Biochemistry, University of Colorado-Boulder, Boulder, Colorado, United States of America
| | - Iain Miller
- Department of Chemistry and Biochemistry, University of Colorado-Boulder, Boulder, Colorado, United States of America
| | - Dylan Carter
- Department of Chemistry and Biochemistry, University of Colorado-Boulder, Boulder, Colorado, United States of America
| | - Sabrina L. Spencer
- Department of Chemistry and Biochemistry, University of Colorado-Boulder, Boulder, Colorado, United States of America
| |
Collapse
|
41
|
Moser J, Hoffmann B, Andresen D, Kuck KH, Brachmann J, Eckardt L, Hoffmann E, Lewalter T, Schumacher B, Spitzer S, Hochadel M, Senges J, Willems S. P786Factors associated with acute pacemaker implantation after carvo- tricuspidal isthmus ablation - results from the German ablation registry. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Moser J, Hoffmann B, Andresen D, Brachmann J, Eckardt L, Hoffmann E, Kuck KH, Lewalter T, Schumacher B, Spitzer S, Hochadel M, Senges J, Willems S. P2672Which factors are associated with acute pacemaker implantation after ablation of atrial fibrillation? Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
43
|
Moser J, Schaeffer B, Akbulak R, Nuerich J, Eickholt C, Jularic M, Willems S, Hoffmann B. P804Sedation monitoring with processed electroencephalogram signals under propofol sedation: a potential benefit on mapping and catheter ablation of ventricular premature contractions. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Moser J, Hoffmann B, Andresen D, Brachmann J, Eckardt L, Hoffmann E, Kuck K, Lewalter T, Schumacher B, Spitzer S, Hochadel M, Senges J, Willems S. P783Influencing factors of in-hospital pacemaker implantation after ablation of AV-nodal reentry- and AV-reentry tachycardia: results from the German ablation registry. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Carr A, Cooper C, Campbell MK, Rees J, Moser J, Beard DJ, Fitzpatrick R, Gray A, Dawson J, Murphy J, Bruhn H, Cooper D, Ramsay C. Effectiveness of open and arthroscopic rotator cuff repair (UKUFF): a randomised controlled trial. Bone Joint J 2017; 99-B:107-115. [PMID: 28053265 DOI: 10.1302/0301-620x.99b1.bjj-2016-0424.r1] [Citation(s) in RCA: 67] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/12/2016] [Accepted: 09/23/2016] [Indexed: 11/05/2022]
Abstract
AIMS The appropriate management for patients with a degenerative tear of the rotator cuff remains controversial, but operative treatment, particularly arthroscopic surgery, is increasingly being used. Our aim in this paper was to compare the effectiveness of arthroscopic with open repair of the rotator cuff. PATIENTS AND METHODS A total of 273 patients were recruited to a randomised comparison trial (136 to arthroscopic surgery and 137 to open surgery) from 19 teaching and general hospitals in the United Kingdom. The surgeons used their usual preferred method of repair. The Oxford Shoulder Score (OSS), two years post-operatively, was the primary outcome measure. Imaging of the shoulder was performed at one year after surgery. The trial is registered with Current Controlled Trials, ISRCTN97804283. RESULTS The mean OSS improved from 26.3 (standard deviation (sd) 8.2) at baseline, to 41.7 (sd 7.9) two years post-operatively for arthroscopic surgery and from 25.0 (sd 8.0) to 41.5 (sd 7.9) for open surgery. Intention-to-treat (ITT) analysis showed no statistical difference between the groups at two years (difference in OSS score -0.76; 95% confidence interval (CI) -2.75 to 1.22; p = 0.452). The confidence interval excluded the pre-determined clinically important difference in the OSS of three points. The rate of re-tear was not significantly different between the two groups (46.4% for arthroscopic and 38.6% for open surgery; 95% CI -6.9 to 25.8; p = 0.256). Healed repairs had the most improved OSS. These findings were the same when analysed per-protocol. CONCLUSION There is no evidence of difference in effectiveness between open and arthroscopic repair of rotator cuff tears. The rate of re-tear is high in both groups, for all sizes of tear and ages and this adversely affects the outcome. Cite this article: Bone Joint J 2017;99-B:107-15.
Collapse
Affiliation(s)
- A Carr
- University of Oxford, Botnar Research Centre, Windmill Road, Headington, Oxford OX3 7LD, UK
| | - C Cooper
- University of Oxford, Botnar Research Centre, Windmill Road, Headington, Oxford OX3 7LD, UK
| | - M K Campbell
- University of Aberdeen, Health Services Research Unit, Foresterhill, Aberdeen, AB25 2ZD, UK
| | - J Rees
- University of Oxford, Botnar Research Centre, Windmill Road, Headington, Oxford OX3 7LD, UK
| | - J Moser
- Nuffield Orthopaedic Centre, Oxford University Hospitals Trust, Windmill Road, Headington, Oxford, OX3 7HE, UK
| | - D J Beard
- University of Oxford, Botnar Research Centre, Windmill Road, Headington, Oxford OX3 7LD, UK
| | - R Fitzpatrick
- University of Oxford, Richard Doll Building, Old Road Campus, Oxford, OX3 7LF, UK
| | - A Gray
- University of Oxford, Richard Doll Building, Old Road Campus, Oxford, OX3 7LF, UK
| | - J Dawson
- University of Oxford, Old Road Campus, OX3 7LF, UK
| | - J Murphy
- University of Oxford, Old Road Campus, OX3 7LF, UK
| | - H Bruhn
- University of Aberdeen, Health Services Research Unit, Foresterhill, Aberdeen, AB25 2ZD, UK
| | - D Cooper
- University of Aberdeen, Health Services Research Unit, Foresterhill, Aberdeen, AB25 2ZD, UK
| | - C Ramsay
- University of Aberdeen, Health Services Research Unit, Foresterhill, Aberdeen, AB25 2ZD, UK
| |
Collapse
|
46
|
Lindblom SC, Shurson GC, Moser J, Kerr BJ. 0960 Kinetics of lipid peroxidation in fats and oils as affected by lipid source, heating temperature, and length of heating. J Anim Sci 2016. [DOI: 10.2527/jam2016-0960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Gunawardene M, Willems S, Schäffer B, Moser J, Akbulak RÖ, Jularic M, Eickholt C, Nührich J, Meyer C, Kuklik P, Sehner S, Czerner V, Hoffmann BA. Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation. Clin Res Cardiol 2016; 106:38-48. [PMID: 27435077 DOI: 10.1007/s00392-016-1021-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Accepted: 07/08/2016] [Indexed: 12/31/2022]
Abstract
BACKGROUND The use of non-vitamin K antagonists (NOACs), uninterrupted (uVKA) and interrupted vitamin K antagonists (iVKA) are common periprocedural oral anticoagulation (OAC) strategies for atrial fibrillation (AF) ablation. Comparative data on complication rates resulting from OAC strategies for solely persistent AF (persAF) undergoing ablation are sparse. Thus, we sought to determine the impact of these OAC strategies on complication rates among patients with persAF undergoing catheter ablation. METHODS Consecutive patients undergoing persAF ablation were included. Depending on preprocedural OAC, three groups were defined: (1) NOACs (paused 48 h preablation), (2) uVKA, and (3) iVKA with heparin bridging. A combined complication endpoint (CCE) composed of bleeding and thromboembolic events was analyzed. RESULTS Between 2011 and 2014, 1440 persAF ablation procedures were performed in 1092 patients. NOACs were given in 441 procedures (31 %; rivaroxaban 57 %, dabigatran 33 %, and apixaban 10 %), uVKA in 488 (34 %), and iVKA in 511 (35 %). Adjusted CCE rates were 5.5 % [95 % confidence interval (CI) (3.1-7.8)] in group 1 (NOACs), 7.5 % [95 % CI (5.0-10.1)] in group 2 (uVKA), and 9.9 % [95 % CI (6.6-13.2)] in group 3. Compared to group 1, the combined complication risk was almost twice as high in group 3 [odd's ratio (OR) 1.9, 95 % CI (1.0-3.7), p = 0.049)]. The major complication rate was low (0.9 %). Bleeding complications, driven by minor groin complications, are more frequent than thromboembolic events (n = 112 vs. 1, p < 0.0001). CONCLUSIONS Patients undergoing persAF ablation with iVKA anticoagulation have an increased risk of complications compared to NOACs. Major complications, such as thromboembolic events, are generally rare and are exceeded by minor bleedings.
Collapse
Affiliation(s)
- Melanie Gunawardene
- Department of Cardiology-Electrophysiology, University Heart Center Hamburg, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20251, Hamburg, Germany.
| | - S Willems
- Department of Cardiology-Electrophysiology, University Heart Center Hamburg, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20251, Hamburg, Germany
| | - B Schäffer
- Department of Cardiology-Electrophysiology, University Heart Center Hamburg, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20251, Hamburg, Germany
| | - J Moser
- Department of Cardiology-Electrophysiology, University Heart Center Hamburg, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20251, Hamburg, Germany
| | - R Ö Akbulak
- Department of Cardiology-Electrophysiology, University Heart Center Hamburg, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20251, Hamburg, Germany
| | - M Jularic
- Department of Cardiology-Electrophysiology, University Heart Center Hamburg, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20251, Hamburg, Germany
| | - C Eickholt
- Department of Cardiology-Electrophysiology, University Heart Center Hamburg, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20251, Hamburg, Germany
| | - J Nührich
- Department of Cardiology-Electrophysiology, University Heart Center Hamburg, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20251, Hamburg, Germany
| | - C Meyer
- Department of Cardiology-Electrophysiology, University Heart Center Hamburg, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20251, Hamburg, Germany
| | - P Kuklik
- Department of Cardiology-Electrophysiology, University Heart Center Hamburg, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20251, Hamburg, Germany
| | - S Sehner
- Institute for Medical Biometry and Epidemiology, University Hospital Hamburg Eppendorf, Hamburg, Germany
| | - V Czerner
- Department of Cardiology-Electrophysiology, University Heart Center Hamburg, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20251, Hamburg, Germany
| | - B A Hoffmann
- Department of Cardiology-Electrophysiology, University Heart Center Hamburg, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20251, Hamburg, Germany
| |
Collapse
|
48
|
Moser J, Mansfield AS, Dronca RS, Quevedo F, Kwon ED, Cassivi SD. 11C-Choline PET guided resection of thoracic metastases from prostatic adenocarcinoma. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e16528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Janik S, Schiefer AI, Bekos C, Hacker P, Haider T, Moser J, Klepetko W, Müllauer L, Ankersmit HJ, Moser B. HSP27 and 70 expression in thymic epithelial tumors and benign thymic alterations: diagnostic, prognostic and physiologic implications. Sci Rep 2016; 6:24267. [PMID: 27097982 PMCID: PMC4838882 DOI: 10.1038/srep24267] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Accepted: 03/21/2016] [Indexed: 01/23/2023] Open
Abstract
Thymic Epithelial Tumors (TETs), the most common tumors in the anterior mediastinum in adults, show a unique association with autoimmune Myasthenia Gravis (MG) and represent a multidisciplinary diagnostic and therapeutic challenge. Neither risk factors nor established biomarkers for TETs exist. Predictive and diagnostic markers are urgently needed. Heat shock proteins (HSPs) are upregulated in several malignancies promoting tumor cell survival and metastases. We performed immunohistochemical staining of HSP27 and 70 in patients with TETs (n = 101) and patients with benign thymic alterations (n = 24). Further, serum HSP27 and 70 concentrations were determined in patients with TETs (n = 46), patients with benign thymic alterations (n = 33) and volunteers (n = 49) by using ELISA. HSPs were differentially expressed in histologic types and pathological tumor stages of TETs. Weak HSP tumor expression correlated with worse freedom from recurrence. Serum HSP concentrations were elevated in TETs and MG, correlated with clinical tumor stage and histologic subtype and decreased significantly after complete tumor resection. To conclude, we found HSP expression in the vast majority of TETs, in physiologic thymus and staining intensities in patients with TETs have been associated with prognosis. However, although interesting and promising the role of HSPs in TETs as diagnostic and prognostic or even therapeutic markers need to be further evaluated.
Collapse
Affiliation(s)
- S Janik
- Department of Thoracic Surgery, Division of Surgery, Medical University Vienna, Austria.,Christian Doppler Laboratory for the Diagnosis and Regeneration of Cardiac and Thoracic Diseases, Medical University Vienna, Austria
| | - A I Schiefer
- Clinical Institute of Pathology, Medical University Vienna, Austria
| | - C Bekos
- Department of Thoracic Surgery, Division of Surgery, Medical University Vienna, Austria.,Christian Doppler Laboratory for the Diagnosis and Regeneration of Cardiac and Thoracic Diseases, Medical University Vienna, Austria
| | - P Hacker
- Department of Thoracic Surgery, Division of Surgery, Medical University Vienna, Austria.,Christian Doppler Laboratory for the Diagnosis and Regeneration of Cardiac and Thoracic Diseases, Medical University Vienna, Austria
| | - T Haider
- Christian Doppler Laboratory for the Diagnosis and Regeneration of Cardiac and Thoracic Diseases, Medical University Vienna, Austria.,University Clinic for Trauma Surgery, Medical University Vienna, Austria
| | - J Moser
- Departments of Dermatology and Venereology and Karl Landsteiner Institute of Dermatological Research, Karl Landsteiner University of Health Sciences, St. Pölten, Austria
| | - W Klepetko
- Department of Thoracic Surgery, Division of Surgery, Medical University Vienna, Austria
| | - L Müllauer
- Clinical Institute of Pathology, Medical University Vienna, Austria
| | - H J Ankersmit
- Department of Thoracic Surgery, Division of Surgery, Medical University Vienna, Austria.,Christian Doppler Laboratory for the Diagnosis and Regeneration of Cardiac and Thoracic Diseases, Medical University Vienna, Austria
| | - B Moser
- Department of Thoracic Surgery, Division of Surgery, Medical University Vienna, Austria
| |
Collapse
|
50
|
Moser J, Moshammer R, Koglbauer G, Kitzwögerer M, Bachner M, Trautinger F. Sentinel node biopsy in melanoma: a single-centre experience with 216 consecutive patients. Br J Dermatol 2015; 174:889-91. [PMID: 26402518 DOI: 10.1111/bjd.14189] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- J Moser
- Karl Landsteiner Institute of Dermatological Research, St. Pölten, Austria. .,Department of Dermatology and Venereology, Karl Landsteiner University of Health Sciences, St. Pölten, Austria.
| | - R Moshammer
- Karl Landsteiner Institute of Dermatological Research, St. Pölten, Austria.,Department of Dermatology and Venereology, Karl Landsteiner University of Health Sciences, St. Pölten, Austria
| | - G Koglbauer
- Karl Landsteiner Institute of Dermatological Research, St. Pölten, Austria.,Department of Dermatology and Venereology, Karl Landsteiner University of Health Sciences, St. Pölten, Austria
| | - M Kitzwögerer
- Department of Pathology, Karl Landsteiner University of Health Sciences, St. Pölten, Austria
| | - M Bachner
- Department of Surgery, Karl Landsteiner University of Health Sciences, St. Pölten, Austria
| | - F Trautinger
- Karl Landsteiner Institute of Dermatological Research, St. Pölten, Austria.,Department of Dermatology and Venereology, Karl Landsteiner University of Health Sciences, St. Pölten, Austria
| |
Collapse
|